

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 0 832 253 B9**

(12)

**CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

(15) Correction information:

**Corrected version no 1 (W1 B1)**

**Corrections, see page(s) 23, 30-33**

(48) Corrigendum issued on:

**22.12.2004 Bulletin 2004/52**

(45) Date of publication and mention  
of the grant of the patent:

**19.05.2004 Bulletin 2004/21**

(21) Application number: **96918542.0**

(22) Date of filing: **07.06.1996**

(51) Int Cl.7: **C12N 15/63, A61K 39/12**

(86) International application number:

**PCT/CA1996/000398**

(87) International publication number:

**WO 1996/040945 (19.12.1996 Gazette 1996/55)**

(54) **NUCLEIC ACID RESPIRATORY SYNCYTIAL VIRUS VACCINES**

IMPFSTOFFE FÜR DAS RESPIRATORISCHE-SYNZYTIAL-VIRUS MIT NUKLEIN SÄUREN

VACCINS A ACIDES NUCLEIQUES DU VIRUS RESPIRATOIRE SYNCYTIAL

(84) Designated Contracting States:

**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC  
NL PT SE**

(30) Priority: **07.06.1995 US 476397**

(43) Date of publication of application:

**01.04.1998 Bulletin 1998/14**

(73) Proprietor: **Aventis Pasteur Limited**

**Toronto, Ontario M2R 3T4 (CA)**

(72) Inventors:

- **LI, Xiaomao**  
**Thornhill, Ontario L4J 3E5 (CA)**
- **EWASYSHYN, Mary, E.**  
**Willowdale, Ontario M2R 3N7 (CA)**
- **SAMBHARA, Suryaprakash**  
**Markham, Ontario L3S 1Y1 (CA)**
- **KLEIN, Michel, H.**  
**Willowdale, Ontario M2P 1B9 (CA)**

(74) Representative: **Smart, Peter John et al**

**W.H. BECK, GREENER & CO**  
**7 Stone Buildings**  
**Lincoln's Inn**  
**London WC2A 3SZ (GB)**

(56) References cited:

**WO-A-92/07940**

- **JOURNAL OF GENERAL VIROLOGY 74 (12).**  
**1993. 2559-2565. ISSN: 0022-1317, XP002018434**  
**LOUNSBACH G R ET AL: "Binding of neutralizing**  
**monoclonal antibodies to regions of the fusion**  
**protein of respiratory syncytial virus expressed**  
**in Escherichia coli."**
- **J INFECT DIS 159 (2). 1989. 255-264. CODEN:**  
**JIDIAQ ISSN: 0022-1899, XP002018435 WATHEN**  
**M W ET AL: "IMMUNIZATION OF COTTON RATS**  
**WITH THE HUMAN RESPIRATORY SYNCYTIAL**  
**VIRUS F GLYCOPROTEIN PRODUCED USING A**  
**BACULOVIRUS VECTOR."**
- **J VIROL 61 (2). 1987. 293-301. CODEN: JOVIAM**  
**ISSN: 0022-538X, XP002018436 WERTZ G W ET**  
**AL: "EXPRESSION OF THE FUSION PROTEIN OF**  
**HUMAN RESPIRATORY SYNCYTIAL VIRUS**  
**FROM RECOMBINANT VACCINIA VIRUS**  
**VECTORS AND PROTECTION OF VACCINATED**  
**MICE."**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 0 832 253 B9**

**Description****FIELD OF INVENTION**

**[0001]** The present invention is related to the field of Respiratory Syncytial Virus (RSV) vaccines and is particularly concerned with vaccines comprising nucleic acid sequences encoding the fusion (F) protein of RSV.

**BACKGROUND OF INVENTION**

**[0002]** Respiratory syncytial virus (RSV), a negative-strand RNA virus belonging to the *Paramyxoviridae* family of viruses, is the major viral pathogen responsible for bronchiolitis and pneumonia in infants and young children (ref. 1 - Throughout this application, various references are referred to in parenthesis to more fully describe the state of the art to which this invention pertains. Full bibliographic information for each citation is found at the end of the specification, immediately preceding the claims. Acute respiratory tract infections caused by RSV result in approximately 90,000 hospitalizations and 4,500 deaths per year in the United States (ref. 2). Medical care costs due to RSV infection are greater than \$340 M annually in the United States alone (ref. 3). There is currently no licensed vaccine against RSV. The main approaches for developing an RSV vaccine have included inactivated virus, live-attenuated viruses and subunit vaccines.

**[0003]** The F protein of RSV is considered to be one of the most important protective antigens of the virus. There is a significant similarity (89% identity) in the amino acid sequences of the F proteins from RSV subgroups A and B (ref. 3) and anti-F antibodies can cross-neutralize viruses of both subgroups as well as protect immunized animals against infection with viruses from both subgroups (ref. 4). Furthermore, the F protein has been identified as a major target for RSV-specific cytotoxic T-lymphocytes in mice and humans (ref. 3 and ref. 5).

**[0004]** The use of RSV proteins as vaccines may have obstacles. Parenterally administered vaccine candidates have so far proven to be poorly immunogenic with regard to the induction of neutralizing antibodies in seronegative humans or chimpanzees. The serum antibody response induced by these antigens may be further diminished in the presence of passively acquired antibodies, such as the transplacentally acquired maternal antibodies which most young infants possess. A subunit vaccine candidate for RSV consisting of purified fusion glycoprotein from RSV infected cell cultures and purified by immunoaffinity or ion-exchange chromatography has been described (ref. 6). Parenteral immunization of seronegative or seropositive chimpanzees with this preparation was performed and three doses of 50 µg were required in seronegative animals to induce an RSV serum neutralizing titre of approximately 1:50. Upon subsequent challenge of these animals with wild-type RSV, no effect of immunization on virus shedding or clinical disease could be detected in the upper respiratory tract. The effect of immunization with this vaccine on virus shedding in the lower respiratory tract was not investigated, although this is the site where the serum antibody induced by parenteral immunization may be expected to have its greatest effect. Safety and immunogenicity studies have been performed in a small number of seropositive individuals. The vaccine was found to be safe in seropositive children and in three seronegative children (all > 2.4 years of age). The effects of immunization on lower respiratory tract disease could not be determined because of the small number of children immunized. One immunizing dose in seropositive children induced a 4-fold increase in virus neutralizing antibody titres in 40 to 60% of the vaccinees. Thus, insufficient information is available from these small studies to evaluate the efficacy of this vaccine against RSV-induced disease. A further problem facing subunit RSV vaccines is the possibility that inoculation of seronegative subjects with immunogenic preparations might result in disease enhancement (sometimes referred to as immunopotential), similar to that seen in formalin inactivated RSV vaccines. In some studies, the immune response to immunization with RSV F protein or a synthetic RSV FG fusion protein resulted in a disease enhancement in rodents resembling that induced by a formalin-inactivated RSV vaccine. The association of immunization with disease enhancement using non-replicating antigens suggests caution in their use as vaccines in seronegative humans.

**[0005]** Live attenuated vaccines against disease caused by RSV may be promising for two main reasons. Firstly, infection by a live vaccine virus induces a balanced immune response comprising mucosal and serum antibodies and cytotoxic T-lymphocytes. Secondly, infection of infants with live attenuated vaccine candidates or naturally acquired wild-type virus is not associated with enhanced disease upon subsequent natural reinfection. It will be challenging to produce live attenuated vaccines that are immunogenic for younger infants who possess maternal virus-neutralizing antibodies and yet are attenuated for seronegative infants greater than or equal to 6 months of age. Attenuated live virus vaccines also have the risks of residual virulence and genetic instability.

**[0006]** Injection of plasmid DNA containing sequences encoding a foreign protein has been shown to result in expression of the foreign protein and the induction of antibody and cytotoxic T-lymphocyte responses to the antigen in a number of studies (see, for example, refs. 7, 8, 9). The use of plasmid DNA inoculation to express viral proteins for the purpose of immunization may offer several advantages over the strategies summarized above. Firstly, DNA encoding a viral antigen can be introduced in the presence of antibody to the virus itself, without loss of potency due to

neutralization of virus by the antibodies. Secondly, the antigen expressed *in vivo* should exhibit a native conformation and, therefore, should induce an antibody response similar to that induced by the antigen present in the wild-type virus infection. In contrast, some processes used in purification of proteins can induce conformational changes which may result in the loss of immunogenicity of protective epitopes and possibly immunopotentiality. Thirdly, the expression of proteins from injected plasmid DNAs can be detected *in vivo* for a considerably longer period of time than that in virus-infected cells, and this has the theoretical advantage of prolonged cytotoxic T-cell induction and enhanced antibody responses. Fourthly, *in vivo* expression of antigen may provide protection without the need for an extrinsic adjuvant.

**[0007]** The ability to immunize against disease caused by RSV by administration of a DNA molecule encoding an RSV F protein was unknown before the present invention. In particular, the efficacy of immunization against RSV induced disease using a gene encoding a secreted form of the RSV F protein was unknown. Infection with RSV leads to serious disease. It would be useful and desirable to provide isolated genes encoding RSV F protein and vectors for *in vivo* administration for use in immunogenic preparations, including vaccines, for protection against disease caused by RSV and for the generation of diagnostic reagents and kits. In particular, it would be desirable to provide vaccines that are immunogenic and protective in humans, including seronegative infants, that do not cause disease enhancement (immunopotentiality).

### SUMMARY OF INVENTION

**[0008]** The present invention relates to a means of immunizing a host against disease caused by respiratory syncytial virus, to nucleic acid molecules used therein, and to diagnostic procedures utilizing the nucleic acid molecules. In particular, the present invention is directed towards the provision of nucleic acid respiratory syncytial virus plasmid vectors.

**[0009]** In accordance with one aspect of the invention, there is provided a plasmid vector, comprising:

- a first nucleotide sequence encoding an RSV F protein or a protein capable of inducing antibodies that specifically react with RSV F protein;
- a promoter sequence operatively coupled to the first nucleotide sequence for expression of the RSV F protein, and
- a second nucleotide sequence located adjacent the first nucleotide sequence to enhance the immunoprotective ability of the RSV F protein when expressed *in vivo* from the vector in a host.

**[0010]** The first nucleotide sequence may be that which encodes a full-length RSV F protein, as seen in Figure 2 (SEQ ID No: 2). Alternatively, the first nucleotide sequence may be that which encodes an RSV F protein from which the transmembrane region is absent. The latter embodiment may be provided by a nucleotide sequence which encodes a full-length RSV F protein but contains a translational stop codon immediately upstream of the start of the transmembrane coding region, thereby preventing expression of a transmembrane region of the RSV F protein, as seen in Figure 3 (SEQ. ID No. 4). The lack of expression of the transmembrane region results in a secreted form of the RSV F protein.

**[0011]** The second nucleotide sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing, whereby substantially all transcribed mRNA encodes the RSV protein. Such second nucleotide sequence may be located between the first nucleotide sequence and the promoter sequence. Such second nucleotide sequence may be that of rabbit  $\beta$ -globin intron II, as shown in Figure 8 (SEQ ID No: 5).

**[0012]** A vector encoding the F protein and provided by this aspect of the invention may specifically be pXL2 or pXL4, as seen in Figures 5 or 7.

**[0013]** The promoter sequence may be an immediate early cytomegalovirus (CMV) promoter. Such cytomegalovirus promoter has not previously been employed in vectors containing nucleotide sequences encoding an RSV F protein.

**[0014]** Accordingly, in another aspect of the invention, there is provided a plasmid vector, comprising:

- a first nucleotide sequence encoding an RSV F protein or a protein capable of generating antibodies that specifically react with RSV F protein, and
- a cytomegalovirus promoter operatively coupled to the first nucleotide sequence for expression of the RSV F protein.

**[0015]** The first nucleotide sequence may be any of the alternatives described above. The second nucleotide sequence, included to enhance the immunoprotective ability of the RSV F protein when expressed *in vivo* from the vector in a host, described above also may be present located adjacent a first nucleotide sequence in a vector provided in accordance with this second aspect of the invention.

**[0016]** Certain of the vectors provided herein may be used to immunize a host against RSV infection or disease by *in vivo* expression of RSV F protein lacking a transmembrane region following administration of the vectors. In accordance with a further aspect of the present invention, therefore, there is provided a method of immunizing a host against

disease caused by infection with respiratory syncytial virus, which comprises administering to the host an effective amount of a vector comprising a first nucleotide sequence encoding an RSV F protein, a protein capable of generating antibodies that specifically react with RSV F protein or an RSV F protein lacking a transmembrane region and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the RSV F protein in the host, which may be a human. The promoter may be an immediate early cytomegalovirus promoter.

**[0017]** The nucleotide sequence encoding the truncated RSV F protein lacking the transmembrane region may be that as described above.

**[0018]** A vector containing a second nucleotide sequence located adjacent a first nucleotide sequence encoding an RSV F protein, a protein capable of inducing antibodies that specifically react with RSV F protein or an RSV F protein lacking a transmembrane region and effective to enhance the immunoprotective ability of the RSV F protein expressed by the first nucleotide sequence may be used to immunize a host. Accordingly, in an additional aspect of the present invention, there is provided a method of immunizing a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises administering to the host an effective amount of a vector comprising a first nucleotide sequence encoding an RSV F protein, a protein capable of generating antibodies that specifically react with RSV F protein or an RSV F protein lacking a transmembrane region, a promoter sequence operatively coupled to the first nucleotide sequence for expression of the RSV F protein, and a second nucleotide sequence located adjacent the first sequence to enhance the immunoprotective ability of the RSV-F protein when expressed *in vivo* from said vector in said host. Specific vectors which may be used in this aspect of the invention are those identified as pXL2 and pXL4 in Figures 5 and 7.

**[0019]** In addition, the present invention includes a method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus, which comprises:

isolating a first nucleotide sequence encoding an RSV F protein, a protein capable of generating antibodies that specifically react with RSV F protein or an RSV F protein lacking a transmembrane region;

operatively linking the first nucleotide sequence to at least one control sequence to produce a vector, the control sequence directing expression of the RSV F protein when introduced into a host to produce an immune response to the RSV F protein when expressed *in vivo* from the vector in a host, and  
formulating the vector as a vaccine for *in vivo* administration.

**[0020]** The first nucleotide sequence further may be operatively linked to a second nucleotide sequence to enhance the immunoprotective ability of the RSV F protein when expressed *in vivo* from the vector in a host. The vector may be selected from pXL1, pXL2 and pXL4. The invention further includes a vaccine for administration to a host, including a human host, produced by this method as well as immunogenic compositions comprising an immunoeffective amount of the vectors described herein.

**[0021]** As noted previously, the vectors provided herein are useful in diagnostic applications. In a further aspect of the invention, therefore, there is provided a method of determining the presence of an RSV F protein in a sample, comprising the steps of:

(a) immunizing a host with a vector comprising a first nucleotide sequence encoding an RSV F protein, a protein capable of generating antibodies that specifically react with RSV F protein or an RSV F protein lacking a transmembrane region and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the RSV F protein in the host to produce antibodies specific for the RSV F protein;

(b) isolating the RSV F protein specific antibodies;

(c) contacting the sample with the isolated antibodies to produce complexes comprising any RSV F protein present in the sample and the RSV F protein- specific antibodies; and

(d) determining production of the complexes.

The vector employed to elicit the antibodies may be pXL1, pXL2, pXL3 or pXL4.

**[0022]** The invention also includes a diagnostic kit for detecting the presence of an RSV F protein in a sample, comprising:

(a) a vector comprising a first nucleotide sequence encoding an RSV F protein, a protein capable of generating antibodies that specifically react with RSV F protein, or a RSV F protein lacking a transmembrane region and a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV F protein in a host immunized therewith to produce antibodies specific for the RSV F protein;

(b) isolation means to isolate said RSV F protein specific antibodies;

(c) contacting means to contact the isolated RSV F specific antibodies with the sample to produce a complex comprising any RSV F protein present in the sample and RSV F protein specific antibodies; and

(d) identifying means to determine production of the complex.

**[0023]** In this application, the term "RSV F protein" is used to define a full-length RSV F protein, such proteins having variations in their amino acid sequences including those naturally occurring in various strains of RSV, a secreted form of RSV F protein lacking a transmembrane region, as well as functional analogs of the RSV F protein. In this application, a first protein is a "functional analog" of a second protein if the first protein is immunologically related to and/or has the same function as the second protein. The functional analog may be, for example, a fragment of the protein or a substitution, addition or deletion mutant thereof.

#### BRIEF DESCRIPTION OF THE FIGURES

**[0024]** The present invention will be further understood from the following General Description and Examples with reference to the Figures in which:

Figure 1 illustrates a restriction map of the gene encoding the F protein of Respiratory Syncytial Virus;  
 Figure 2 illustrates the nucleotide sequence of the gene encoding the membrane attached form of the F protein of Respiratory Syncytial Virus (SEQ ID No: 1) as well as the amino acid sequence of the RSV F protein encoded thereby (SEQ ID No: 2);  
 Figure 3 illustrates the nucleotide sequence of the gene encoding the secreted form of the RSV F protein lacking the transmembrane region (SEQ ID No: 3) as well as the amino acid sequence of the truncated RSV F protein lacking the transmembrane region encoded thereby (SEQ ID No: 4);  
 Figure 4 shows the construction of plasmid pXL1 containing the gene encoding a secreted form of the RSV F protein lacking the transmembrane region;  
 Figure 5 shows the construction of plasmid pXL2 containing a gene encoding a secreted form of the RSV F protein lacking the transmembrane region and containing the rabbit  $\beta$ -globin Intron II sequence;  
 Figure 6 shows the construction of plasmid pXL3 containing the gene encoding a full length membrane attached form of the RSV F protein;  
 Figure 7 shows the construction of plasmid pXL4 containing a gene encoding a membrane attached form of the RSV F protein and containing the rabbit  $\beta$ -globin Intron II sequence; and  
 Figure 8 shows the nucleotide sequence for the rabbit  $\beta$ -globin Intron II sequence (SEQ ID No. 5).

#### GENERAL DESCRIPTION OF INVENTION

**[0025]** As described above, the present invention relates generally to polynucleotide, including DNA, immunization to obtain protection against infection by respiratory syncytial virus (RSV) and to diagnostic procedures using particular vectors. In the present invention, several recombinant vectors were constructed to contain a nucleotide sequence encoding an RSV F protein.

**[0026]** The nucleotide sequence of the full length RSV F gene is shown in Figure 2 (SEQ ID No: 1). Certain constructs provided herein include the nucleotide sequence encoding the full-length RSV F (SEQ ID No: 2) protein while others include an RSV F gene modified by insertion of termination codons immediately upstream of the transmembrane coding region (see Figure 3, SEQ ID No: 3), to prevent expression of the transmembrane portion of the protein and to produce a secreted or truncated RSV F protein lacking a transmembrane region (SEQ ID No. 4).

**[0027]** The nucleotide sequence encoding the RSV F protein is operatively coupled to a promoter sequence for expression of the encoded RSV F protein. The promoter sequence may be the immediately early cytomegalovirus (CMV) promoter. This promoter is described in ref. 13. Any other convenient promoter may be used, including constitutive promoters, such as, Rous Sarcoma Virus LTRs, and inducible promoters, such as metallothioneine promoter, and tissue specific promoters.

**[0028]** The vectors provided herein, when administered to an animal, effect *in vivo* RSV F protein expression, as demonstrated by an antibody response in the animal to which it is administered. Such antibodies may be used herein in the detection of RSV protein in a sample, as described in more detail below. When the encoded RSV F protein is in the form of an RSV F protein from which the transmembrane region is absent, such as plasmid pXL1 (Figure 4), the administration of the vector conferred protection in mice and cotton rats to challenge by live RSV virus neutralizing antibody and cell mediated immune responses and an absence of immunopotentiality in immunized animals, as seen from the Examples below.

**[0029]** The recombinant vector also may include a second nucleotide sequence located adjacent the RSV F protein encoding nucleotide sequence to enhance the immunoprotective ability of the RSV F protein when expressed *in vivo* in a host. Such enhancement may be provided by increased *in vivo* expression, for example, by increased mRNA stability, enhanced transcription and/or translation. This additional sequence preferably is located between the promoter

sequence and the RSV F protein-encoding sequence.

**[0030]** This enhancement sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing during transcription and translation so that substantially all transcribed mRNA encodes an RSV F protein. Specifically, rabbit  $\beta$ -globin Intron II sequence shown in Figure 7 (SEQ ID No: 5) may provide such splice sites, as also described in ref. 15.

**[0031]** The constructs containing the Intron II sequence, CMV promoter and nucleotide sequence coding for the truncated RSV F protein lacking a transmembrane region, i.e. plasmid pXL2 (Figure 5), induced complete protection in mice against challenge with live RSV, as seen in the Examples below. In addition, the constructs containing the Intron II sequence, CMV promoter and nucleotide sequence coding for the full-length RSV F protein, i.e. plasmid pXL4 (Figure 7), also conferred protection in mice to challenge with live RSV, as seen from the Examples below.

**[0032]** The vector provided herein may also comprise a third nucleotide sequence encoding a further antigen from RSV, an antigen from at least one other pathogen or at least one immunomodulating agent, such as cytokine. Such vector may contain said third nucleotide sequence in a chimeric or a bicistronic structure. Alternatively, vectors containing the third nucleotide sequence may be separately constructed and coadministered to a host, with the nucleic acid molecule provided herein.

**[0033]** The vector may further comprise a nucleotide sequence encoding a heterologous signal peptide, such as human tissue plasminogen activator (TPA), in place of the endogenous signal peptide.

**[0034]** It is clearly apparent to one skilled in the art, that the various embodiments of the present invention have many applications in the fields of vaccination, diagnosis and treatment of RSV infections. A further non-limiting discussion of such uses is further presented below.

## 1. Vaccine Preparation and Use

**[0035]** Immunogenic compositions, suitable to be used as vaccines, may be prepared from the RSV F genes and vectors as disclosed herein. The vaccine elicits an immune response in a subject which includes the production of anti-F antibodies. Immunogenic compositions, including vaccines, containing the nucleic acid may be prepared as injectables, in physiologically-acceptable liquid solutions or emulsions for polynucleotide administration. The nucleic acid may be associated with liposomes, such as lecithin liposomes or other liposomes known in the art, as a nucleic acid liposome (for example, as described in WO 9324640, ref. 17) or the nucleic acid may be associated with an adjuvant, as described in more detail below. Liposomes comprising cationic lipids interact spontaneously and rapidly with polyanions such as DNA and RNA, resulting in liposome/nucleic acid complexes that capture up to 100% of the polynucleotide. In addition, the polycationic complexes fuse with cell membranes, resulting in an intracellular delivery of polynucleotide that bypasses the degradative enzymes of the lysosomal compartment. Published PCT application WO 94/27435 describes compositions for genetic immunization comprising cationic lipids and polynucleotides. Agents which assist in the cellular uptake of nucleic acid, such as calcium ions, viral proteins and other transfection facilitating agents, may advantageously be used.

**[0036]** Polynucleotide immunogenic preparations may also be formulated as microcapsules, including biodegradable time-release particles. Thus, U.S. Patent 5,151,264 describes a particulate carrier of a phospholipid/glycolipid/polysaccharide nature that has been termed Bio Vecteurs Supra Moléculaires (BVSM). The particulate carriers are intended to transport a variety of molecules having biological activity in one of the layers thereof.

**[0037]** U.S. Patent 5,075,109 describes encapsulation of the antigens trinitrophenylated keyhole limpet hemocyanin and staphylococcal enterotoxin B in 50:50 poly (DL-lactide-co-glycolide). Other polymers for encapsulation are suggested, such as poly(glycolide), poly(DL-lactide-co-glycolide), copolyoxalates, polycaprolactone, poly(lactide-co-caprolactone), poly(esteramides), polyorthoesters and poly(8-hydroxybutyric acid), and polyanhydrides.

**[0038]** Published PCT application WO 91/06282 describes a delivery vehicle comprising a plurality of bioadhesive microspheres and antigens. The microspheres being of starch, gelatin, dextran, collagen or albumin. This delivery vehicle is particularly intended for the uptake of vaccine across the nasal mucosa. The delivery vehicle may additionally contain an absorption enhancer.

**[0039]** The RSV F genes and vectors may be mixed with pharmaceutically acceptable excipients which are compatible therewith. Such excipients may include, water, saline, dextrose, glycerol, ethanol, and combinations thereof. The immunogenic compositions and vaccines may further contain auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, or adjuvants to enhance the effectiveness thereof. Immunogenic compositions and vaccines may be administered parenterally, by injection subcutaneously, intravenously, intradermally or intramuscularly, possibly following pretreatment of the injection site with a local anesthetic. Alternatively, the immunogenic compositions formed according to the present invention, may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces. Thus, the immunogenic composition may be administered to mucosal surfaces by, for example, the nasal or oral (intragastric) routes. Alternatively, other modes of administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example, polyalkylene glycols or triglycerides. Oral formulations may include normally employed excipients, such as, for example, pharmaceutical

grades of saccharine, cellulose and magnesium carbonate.

**[0040]** The immunogenic preparations and vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective, protective and immunogenic. The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize the RSV F protein and antibodies thereto, and if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of about 1 µg to about 1 mg of the RSV F genes and vectors. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations. The dosage may also depend on the route of administration and will vary according to the size of the host. A vaccine which protects against only one pathogen is a monovalent vaccine. Vaccines which contain antigenic material of several pathogens are combined vaccines and also belong to the present invention. Such combined vaccines contain, for example, material from various pathogens or from various strains of the same pathogen, or from combinations of various pathogens.

**[0041]** Immunogenicity can be significantly improved if the vectors are co-administered with adjuvants, commonly used as 0.05 to 0.1 percent solution in phosphate-buffered saline. Adjuvants enhance the immunogenicity of an antigen but are not necessarily immunogenic themselves. Adjuvants may act by retaining the antigen locally near the site of administration to produce a depot effect facilitating a slow, sustained release of antigen to cells of the immune system. Adjuvants can also attract cells of the immune system to an antigen depot and stimulate such cells to elicit immune responses.

**[0042]** Immunostimulatory agents or adjuvants have been used for many years to improve the host immune responses to, for example, vaccines. Thus, adjuvants have been identified that enhance the immune response to antigens. Some of these adjuvants are toxic, however, and can cause undesirable side-effects, making them unsuitable for use in humans and many animals. Indeed, only aluminum hydroxide and aluminum phosphate (collectively commonly referred to as alum) are routinely used as adjuvants in human and veterinary vaccines.

**[0043]** A wide range of extrinsic adjuvants and other immunomodulating material can provoke potent immune responses to antigens. These include saponins complexed to membrane protein antigens to produce immune stimulating complexes (ISCOMS), pluronic polymers with mineral oil, killed mycobacteria in mineral oil, Freund's complete adjuvant, bacterial products, such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS), as well as monophoryl lipid A, QS 21 and polyphosphazene.

**[0044]** In particular embodiments of the present invention, the vector comprising a first nucleotide sequence encoding an F protein of RSV may be delivered in conjunction with a targeting molecule to target the vector to selected cells including cells of the immune system.

**[0045]** The polynucleotide may be delivered to the host by a variety of procedures, for example, Tang et al. (ref. 10) disclosed that introduction of gold microprojectiles coated with DNA encoding bovine growth hormone (BGH) into the skin of mice resulted in production of anti-BGH antibodies in the mice, while Furth et al. (ref. 11) showed that a jet injector could be used to transfect skin, muscle, fat and mammary tissues of living animals.

## 2. Immunoassays

**[0046]** The RSV F genes and vectors of the present invention are useful as immunogens for the generation of anti-F antibodies for use in immunoassays, including enzyme-linked immunosorbent assays (ELISA), RIAs and other non-enzyme linked antibody binding assays or procedures known in the art. In ELISA assays, the vector first is administered to a host to generate antibodies specific to the RSV F protein. These RSV F-specific antibodies are immobilized onto a selected surface, for example, a surface capable of binding the antibodies, such as the wells of a polystyrene microtiter plate. After washing to remove incompletely adsorbed antibodies, a nonspecific protein such as a solution of bovine serum albumin (BSA) that is known to be antigenically neutral with regard to the test sample may be bound to the selected surface. This allows for blocking of nonspecific adsorption sites on the immobilizing surface and thus reduces the background caused by nonspecific bindings of antisera onto the surface.

**[0047]** The immobilizing surface is then contacted with a sample, such as clinical or biological materials, to be tested in a manner conducive to immune complex (antigen/antibody) formation. This procedure may include diluting the sample with diluents, such as solutions of BSA, bovine gamma globulin (BGG) and/or phosphate buffered saline (PBS)/Tween. The sample is then allowed to incubate for from about 2 to 4 hours, at temperatures such as of the order of about 20° to 37°C. Following incubation, the sample-contacted surface is washed to remove non-immunocomplexed material. The washing procedure may include washing with a solution, such as PBS/Tween or a borate buffer. Following formation of specific immunocomplexes between the test sample and the bound RSV F specific antibodies, and subsequent washing, the occurrence, and even amount, of immunocomplex formation may be determined.

BIOLOGICAL MATERIALS

**[0048]** Certain plasmids that contain the gene encoding RSV F protein and referred to herein have been deposited with the America Type Culture Collection (ATCC) located at 12301 Parklawn Drive, Rockville, Maryland, 20852, U.S. A., pursuant to the Budapest Treaty and prior to the filing of this application.

**[0049]** Samples of the deposited plasmids will become available to the public upon grant of a patent based upon this United States patent application and all restrictions on access to the deposits will be removed at that time. The invention described and claimed herein is not to be limited in scope by plasmids deposited, since the deposited embodiment is intended only as an illustration of the invention. Any equivalent or similar plasmids that encode similar or equivalent antigens as described in this application are within the scope of the invention.

Plasmid	ATCC Designation	Date Deposited
pXL1	97167	May 30, 1995
pXL2	97168	May 30, 1995
pXL3	97169	May 30, 1995
pXL4	97170	May 30, 1995.

EXAMPLES

**[0050]** The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitations.

**[0051]** Methods of molecular genetics, protein biochemistry, and immunology used but not explicitly described in this disclosure and these Examples are amply reported in the scientific literature and are well within the ability of those skilled in the art.

Example 1

**[0052]** This Example describes the construction of vectors containing the RSV F gene.

**[0053]** Figure 1 shows a restriction map of the gene encoding the F protein of Respiratory Syncytial Virus and Figure 2 shows the nucleotide sequence of the gene encoding the full-length RSV F protein (SEQ ID No: 1) and the deduced amino acid sequence (SEQ ID No: 2). Figure 3 shows the gene encoding the secreted RSV F protein (SEQ ID No: 3) and the deduced amino acid sequence (SEQ ID No: 4).

**[0054]** A set of four plasmid DNA constructs were made (as shown schematically in Figures 4 to 7) in which cDNA encoding the RSV-F was subcloned downstream of the immediate-early promoter, enhancer and intron A sequences of human cytomegalovirus (CMV) and upstream of the bovine growth hormone (BGH) poly-A site. The 1.6 Kb SspI-PstI fragment containing the promoter, enhancer and intron A sequences of CMV Towne strain were initially derived from plasmid pRL43a obtained from Dr. G.S. Hayward of Johns Hopkins University (ref. 20) and subcloned between EcoRV and PstI sites of pBluescript 11 SK +/- (Stratagene). For the construction of plasmids expressing the secretory form of the F protein (pXL1 and pXL2 in Figs. 4 and 5), the 1.6 Kb EcoRI-BamHI fragment containing the truncated form of the F cDNA originally cloned from a clinical isolate belonging to subgroup A was excised from pRSVF (ref. 18 and WO 93/14207) and subcloned between EcoRI and BamHI sites of pSG5 (Stratagene, ref. 14). Either the 1.6 kb EcoRI-BamHI fragment or the 2.2 kb ClaI-BamHI fragment was then excised from the pSG5 construct, filled-in with Klenow and subcloned at the SmaI site of the pBluescript II SK +/- construct containing the promoter and intron A sequences. The 0.6 kb ClaI-EcoRI fragment derived from pSG5 contained the intron II sequences from rabbit  $\beta$ -globin. Subsequently, the plasmids were digested with HindIII, filled-in with Klenow, and digested with XbaI to yield either a 3.2 or a 3.8 Kb fragment. These fragments were used to replace the 0.8 kb NruI-XbaI fragment containing the CMV promoter in pRc/CMV (Invitrogen), resulting in the final pXL1 and pXL2 constructs, respectively.

**[0055]** For the construction of plasmids expressing the full-length F protein (pXL3 and pXL4 - Figs. 6 and 7), the full length RSV F cDNA was excised as a 1.9 kb EcoRI fragment from a recombinant pBluescript M13-SK (Stratagene) containing the insert (ref. 18 and WO 93/14207) and subcloned at the EcoRI site of pSG5 (Stratagene). Either the 1.9 Kb EcoRI fragment or the 2.5 Kb ClaI-BamHI fragment was then excised from the pSG5 construct, filled-in with Klenow and subcloned at the SmaI site of the pBluescript II SK +/- construct containing the promoter and intron A sequences. The rest of the construction for pXL3 and pXL4 was identical to that for pXL1 and pXL2, as described above. Therefore,

except for the CMV promoter and intron A sequences, the rest of the vector components in pXL1-4 were derived from plasmid pRc/CMV. Plasmids pXL1 and pXL2 were made to express a truncated/secretory form of the F protein which carried stop codons resulting in a C-terminal deletion of 48 amino acids including the transmembrane (TM) and the C-terminal cytosolic tail as compared to the intact molecule. In contrast, pXL3 and pXL4 were made to express the intact membrane-attached form of the RSV F molecule containing the TM and the cytosolic C-terminal tail. The rationale for the presence of the intron II sequences in pXL2 and pXL4 was that this intron was reported to mediate the correct splicing of RNAs. Since mRNA for the RSV-F has been suspected to have a tendency towards aberrant splicing, the presence of the intron II sequences might help to overcome this. All four plasmid constructs were confirmed by DNA sequencing analysis.

**[0056]** Plasmid DNA was purified using plasmid mega kits from Qiagen (Chatsworth, CA, USA) according to the manufacturer's instructions.

## Example 2

**[0057]** This Example describes the immunization of mice. Mice are susceptible to infection by RSV as described in ref. 16.

**[0058]** For intramuscular (i.m) immunization, the anterior tibialis anterior muscles of groups of 9 BALB/c mice (male, 6-8 week old) (Jackson Lab., Bar Harbor, ME, USA) were bilaterally injected with 2 x 50 µg (1 µg/µL in PBS) of pXL1-4, respectively. Five days prior to DNA injection, the muscles were treated with 2 x 50 µL (10 µM in PBS) of cardiotoxin (Latoxan, France). Pretreatment of the muscles with cardiotoxin has been reported to increase DNA uptake and to enhance the subsequent immune responses by the intramuscular route (ref. 24). These animals were similarly boosted a month later. Mice in the control group were immunized with a placebo plasmid containing identical vector backbone sequences without the RSV F gene according to the same schedule. For intradermal (i.d.) immunization, 100 µg of pXL2 (2 µg/µL in PBS) were injected into the skin 1-2 cm distal from the tail base. The animals were similarly boosted a month later.

**[0059]** Seventy-five days after the second immunization, mice were challenged intranasally with 10<sup>5.4</sup> plaque forming units (pfu) of mouse-adapted RSV, A2 subtype (obtained from Dr. P. Wyde, Baylor College of Medicine, Houston, TE, USA). Lungs were aseptically removed 4 days later, weighed and homogenized in 2 mL of complete culture medium. The number of pfu in lung homogenates was determined in duplicates as previously described (ref. 19) using vaccine quality Vero cells. These data were subjected to statistic analysis using SigmaStat (Jandel Scientific Software, Guelph, Ont. Canada).

**[0060]** Sera obtained from immunized mice were analyzed for anti-RSV F antibody titres (IgG, IgG1 and IgG2a, respectively) by enzyme-linked immunosorbent assay (ELISA) and for RSV-specific plaque-reduction titres. ELISA were performed using 96-well plates coated with immunoaffinity purified RSV F protein (50 ng/mL) and 2-fold serial dilutions of immune sera. A goat anti-mouse IgG antibody conjugated to alkaline phosphatase (Jackson ImmunoRes., Mississauga, Ont., Canada) was used as secondary antibody. For the measurement of IgG1 and IgG2a antibody titres, the secondary antibodies used were monospecific sheep anti-mouse IgG1 (Serotec, Toronto, Ont., Canada) and rat anti-mouse IgG2a (Zymed, San Francisco, CA, USA) antibodies conjugated to alkaline phosphatase, respectively. Plaque reduction titres were determined according to Prince et al (ref. 19) using vaccine quality Vero cells. Four-fold serial dilutions of immune sera were incubated with 50 pfu of RSV, Long strain (ATCC) in culture medium at 37°C for 1 hr in the presence of 5% CO<sub>2</sub>. Vero cells were then infected with the mixture. Plaques were fixed with 80% methanol and developed 5 days later using a mouse anti-RSV-F monoclonal IgG1 antibody and donkey antimouse IgG antibody conjugated to peroxidase (Jackson ImmunoRes., Mississauga, Ont. Canada). The RSV-specific plaque reduction titre was defined as the dilution of serum sample yielding 60% reduction in the number of plaques. Both ELISA and plaque reduction assays were performed in duplicates and data are expressed as the means of two determinations. These data were subjected to statistic analysis using SigmaStat (Jandel Scientific Software, Guelph, Ont. Canada).

**[0061]** To examine the induction of RSV-specific CTL following DNA immunization, spleens from 2 immunized mice were removed to prepare single cell suspensions which were pooled. Splenocytes were incubated at 2.5 x 10<sup>6</sup> cells/mL in complete RPMI medium containing 10 U/mL murine interleukin 2 (IL-2) with γ-irradiated (3,000 rads) syngeneic splenocytes (2.5 x 10<sup>6</sup> cells/mL) infected with 1 TCID<sub>50</sub>/cell RSV (Long strain) for 2 hr. The source of murine IL-2 was supernatant of a mouse cell line constitutively secreting a high level of IL-2 obtained from Dr. H. Karasuyama of Basel Institute for Immunology (ref. 20). CTL activity was tested 5 days following the *in vitro* re-stimulation in a standard 4 hr chromium release assay. Target cells were 5<sup>1</sup>Cr-labelled uninfected BALB/c fibroblasts (BC cells) and persistently RSV-infected BCH14 fibroblasts, respectively. Washed responder cells were incubated with 2 x 10<sup>3</sup> target cells at varying effector to target ratios in 200 µL in 96-well V-bottomed tissue-culture plates for 4 hr at 37°C. Spontaneous and total chromium releases were determined by incubating target cells with either medium or 2.5% Triton-X 100 in the absence of responder lymphocytes. Percentage specific chromium release was calculated as (counts-spontaneous counts)/(total counts-spontaneous counts) X 100. Tests were performed in triplicates and data are expressed as the

means of three determinations. For antibody blocking studies in CTL assays, the effector cells were incubated for 1 hr with 10 µg/ml final of purified mAb to CD4 (GK1.5) (ref. 21) or mAb against murine CD8 (53-6.7) (ref. 22) before adding chromium labelled BC or BCH4 cells. To determine the effect of anti-class I MHC antibodies on CTL killing, the chromium labelled target cells BC or BCH4 were incubated with 20 µL of culture supernate of hybridoma that secretes a mAb that recognizes K<sup>d</sup> and D<sup>d</sup> of class I MHC (34-1-2S) (ref. 23) prior to the addition of effector cells.

### Example 3

**[0062]** This Example describes the immunogenicity and protection by polynucleotide immunization by the intramuscular route.

**[0063]** To characterize the antibody responses following i.m. DNA administration, immune sera were analyzed for anti-RSV F IgG antibody titre by ELISA and for RSV-specific plaque reduction titre, respectively. All four plasmid constructs were found to be immunogenic. Sera obtained from mice immunized with pXL1-4 demonstrated significant anti-RSV F IgG titres and RSV-specific plaque reduction titres as compared to the placebo group (Table 1 below) (P<0.0061 and <0.0001, respectively, Mann-Whitney Test). However, there is no significant difference in either anti-RSV F IgG titre or RSV-specific plaque reduction titre among mice immunized with either pXL1, pXL2, pXL3 or pXL4.

**[0064]** To evaluate the protective ability of pXL1-4 against primary RSV infection of the lower respiratory tract, immunized mice were challenged intranasally with mouse-adapted RSV and viral lung titres post challenge were assessed. All four plasmid constructs were found to protect animals against RSV infection. A significant reduction in the viral lung titre was observed in mice immunized with pXL1-4 as compared to the placebo group (P<0.0001, Mann-Whitney Test). However, varying degrees of protection were observed depending on the plasmid. In particular, PXL1 was more protective than pXL3 (P=0.00109, Mann-Whitney Test), and pXL4 more than pXL3 (P=0.00125), whereas only pXL2 induced complete protection. This conclusion was confirmed by another analysis with number of fully protected mice as end point (Fisher Exact Test). Constructs pXL1, pXL2 or pXL4 conferred a higher degree of protection than pXL3 (P<0.004, Fisher Exact Test) which was not more effective than placebo. Only pXL2 conferred full protection in all immunized mice.

**[0065]** The above statistical analysis revealed that PXL1 conferred more significant protection than pXL3. The former expresses the truncated and secretory form and the latter the intact membrane anchored form of the RSV F protein. Furthermore, pXL4 was shown to be more protective than pXL3. The difference between these two constructs is the presence of the intron II sequence in pXL4. Construct pXL2 which expresses the secretory form of the RSV-F in the context of the intron II sequence was the only plasmid that confers complete protection in all immunized mice.

### Example 4

**[0066]** This Example describes the influence of the route of administration of pXL2 on its immunogenicity and protective ability.

**[0067]** The i.m. and i.d. routes of DNA administration were compared for immunogenicity in terms of anti-RSV F antibody titres and RSV-specific plaque reduction titres. Analyses of the immune sera (Table 2 below) revealed that the i.d. route of DNA administration was as immunogenic as the i.m. route as judged by anti-RSV F IgG and IgG1 antibody responses as well as RSV-specific plaque reduction titres. However, only the i.m. route induced significant anti-RSV F IgG2a antibody responses, whereas the IgG2a isotype titre was negligible when the i.d. route was used. The i.m. and i.d. routes were also compared with respect to the induction of RSV-specific CTL. Significant RSV-specific CTL activity was detected in mice immunized intramuscularly. In contrast, the cellular response was significantly lower in mice inoculated intradermally (Table 3 below). In spite of these differences, protection against primary RSV infection of the lower respiratory tract was observed in both groups of mice immunized via either route (Table 4 below). The CTL induced by RSV-F DNA are classical CD8+ class I restricted CTL. The target cells, BCH4 fibroblasts express class I MHC only and do not express class II MHC. Further, prior incubation of BCH4 target cells with anti class-I MHC antibodies significantly blocked the lytic activity of RSV-F DNA induced CTL line. While anti-CD8 antibody could partially block lysis of BCH4 cells, antibody to CD4 molecule had no effect at all (Table 5 below). Lack of total blocking by mAb to CD8 could either be due to CTL being CD8 independent (meaning that even though they are CD8+ CTL, their TCR has enough affinity for class I MHC+peptide and it does not require CD8 interaction with the alpha 3 of class I MHC) or the amount of antibody used in these experiments was limiting. There was no detectable lysis of YAC-1 (NK sensitive target) cells (data not shown).

### Example 5

**[0068]** This Example describes immunization studies in cotton rats using pXL2.

**[0069]** The immune response of cotton rats to DNA immunization was analyzed by the protocol shown in Table 6

below. On day -5, 40 cotton rats were randomly selected and divided into 8 groups of 5. Cotton rats in groups 1 and 7 were inoculated intramuscularly (i.m.) into the tibia anterior (TA) muscles bilaterally with cardiotoxin (1.0 µM). On day -1, the cotton rats in group 8 were inoculated in the TA muscles with bupivacaine (0.25%). On day 0, several animals in each group were bled to determine levels of RSV-specific antibodies in the serum of the test animals prior to administration of vaccines. All of the animals were then inoculated i.m. or intradermally (i.d.) with 200 µg of plasmid DNA, placebo (non-RSV-specific DNA), 100 median cotton rat infectious doses (CRID<sub>50</sub>; positive control) of RSV, or of formalin inactivated RSV prepared in Hep-2 tissue culture cells and adjuvanted in alum. Forty-four days later the cotton rats in groups 1 & 7 were reinoculated with cardiotoxin in the TA muscles. Four days later (48 days after priming with vaccine), the animals in group 8 were reinoculated with bupivacaine in the TA muscle of the right leg. The next day, (seven weeks after priming with vaccine) all of the animals were bled and all, except those in the group given live RSV, were boosted with the same material and doses used on day 0. 29 days later, each cotton rat was bled and then challenged intranasally (i.n.) with 100 CRID<sub>50</sub> RSV A2 grown in Hep-2 tissue culture cells. Four days after this virus challenge (day +88) all of the cotton rats were killed and their lungs removed. One lobe from each set of lungs was fixed in formalin and then processed for histologic evaluation of pulmonary histopathology. The remaining lobes of lung will be assessed for the presence and levels of RSV. Each of the sera collected on days 0, 49 and 78 were tested for RSV-neutralizing activity, anti-RSV fusion activity and RSV-specific ELISA antibody.

**[0070]** The RSV neutralizing titres on day +49 and +78 are shown in Tables 7(a) below and 7(b) below respectively. As can be seen from the results shown in Table 7(a), on day +49 the animals immunized with live RSV and DNA immunization had substantial RSV serum neutralizing titres. The animals immunized with formalin-inactivated RSV had a neutralizing titre equivalent to the placebo group on day +49 but following boosting titres by day +78 had reached 5.8 (log<sub>10</sub>/0.05). Boosting had no significant effect upon animals immunized with live RSV or by i.m. plasmid immunization.

**[0071]** RSV titres in nasal washes (upper respiratory tract) on day +82 are shown in Table 8 below. RSV titres in the lungs (lower respiratory tract) on day +82 are shown in Table 9 below. All of the vaccines provided protection against lung infection but under these conditions, only live virus provided total protection against upper respiratory tract infection.

**[0072]** The lungs from the cotton rats were examined histologically for pulmonary histopathology and the results are shown in Table 10 below. With the exception of lung sections obtained from Group 9 which were essentially free of inflammatory cells or evidence of inflammation, and those from Group 3, which exhibited the maximal pulmonary pathology seen in this study, all of the sections of lung obtained from the other groups looked familiar, i.e. scattered inflammatory cells were present in most fields, and there was some thickening of septae. These are evidence of mild inflammatory diseases. Large numbers of inflammatory cells and other evidence of inflammation were present in sections of lung from Group 3 (in which formalin-inactivated [FI] RSV vaccine was given prior to virus challenge). This result indicated that immunization with plasmid DNA expressing the RSV F protein does not result in pulmonary histopathology different from the placebo, whereas FI-RSV caused more severe pathology.

#### SUMMARY OF THE DISCLOSURE

**[0073]** In summary of this disclosure, the present invention provides certain novel vectors containing genes encoding an RSV F proteins, methods of immunization using such vectors and methods of diagnosis using such vectors. Modifications are possible within the scope of this invention.

Table 1: Immunogenic and Protective Abilities of pXL1-4 Mice via the i.m. Route

Plasmid DNA Immunogen	No. Mice	Mean Anti-RSV F ELISA Titre(IgG)* (Log <sub>2</sub> /100±SD)	Mean Plaque Reduction Titre* (Log <sub>4</sub> ±SD)	Post RSV Challenge	
				Mean Virus Lung Titre# (pfu/g lung ) (Log <sub>10</sub> ±SD)	No. Fully Protected Mice**
pXL1	8	3.00±1.85	3.74±0.98	0.72±0.99	5
pXL2	9	5.78±1.72	4.82±0.51	0.00±0.00	9
pXL3	8	3.75±2.05	4.59±1.16	2.77±0.72	0
pXL4	9	5.44±1.13	5.18±0.43	0.66±1.00	6
Placebo**	12	0.58±2.89	0.18±0.62	3.92±0.27	0

\* These sets of data from sera obtained 1 week prior to the viral challenge

# Detection sensitivity of the assay was 10<sup>1.96</sup> pfu/g lung.

\*\* The term, fully protected mice, refers to animals with no detectable RSV in lungs post challenge.

Table 2. Immunogenicity of pXL2 in Mice\*

Route	No. Mice	Mean Anti-RSV F ELISA Titre (Log <sub>2</sub> /100 + SD)			Mean Plaque Reduction Titre (Log <sub>4</sub> ± SD)
		IgG	IgG1	IgG2a	
i.m	8	7.63±0.92	4.25±1.91	4.38±1.92	4.18±0.88
i.d.	7	7.00±1.00	5.00±1.00	0.14±0.38	3.65±0.59
Placebo (i.m.)	9	0.50±0.51	0.00±0.00	0.00±0.00	0.18±0.50

\* These sets of data are from sera obtained 1 week prior to the viral challenge.

Table 3. Induction of RSV-specific CTL Following DNA Immunization\*

Route	E:T Ratio	% Specific Lysis	
		BC	BCH4
i.m.	200:1	23.3	100.6
	100:1	17.0	62.4
	50:1	19.9	64.1
	25:1	22.3	46.4
i.d.	100:1	20.9	26.1
	50:1	21.7	19.1
	25:1	7.1	7.0
	12.5:1	2.8	2.3

\* These set of data were obtained from immunized mice immediately prior to RSV challenge.

**Table 4. Immunoprotective Ability of pXL2 in Mice**

Route	No. Mice	Post RSV Challenge	
		Mean Virus Lung Titre* (pfu/g lung)	No. Fully Protected Mice#
i.m.	8	0.00 ± 0.00	8
i.d.	7	0.43 ± 1.13	6
Placebo (i.m.)	9	4.30 ± 0.22	0

\* Detection sensitivity of the assay was  $10^{1.69}$  pfu/g lung.

# The term, fully protected mice, refers to animals with no detectable RSV in lungs post challenge.

**Table 5. RSV specific CTL included by i.m. DNA immunization are class I restricted CTL**

E:T Ratio	BCH4	BCH4 + anti-CD4	BCH4 + anti-CD8	BCH4 + anti-class I MHC
100:1	52.03	54.3	39.4	8.6
50:1	44.4	47.2	27.4	6.2
25:1	28.6	26.3	14.8	1
12.5:1	18.2	15	8	-2.7

Table 6

Group	Antigen	RSV-specific dose	Inoc. route	Pretreatment/Adjuvant	Day 0	Day 49	Day 78	Day 88
1	Placebo	0	I.M.	Cardiotoxin	Prebleed, several cotton rats per group; prime all animals	Bleed all animals; boost all except those in group 2	Challenge with RSV A2 I.N. after bleeding all	Harv. animals and do histologic evaluation, pulmonary virus titers, antibodies
2	Live RSV	100 CRID50	I.N.	None				
3	FI-RSV		I.M.	Alum				
5	pXL2	200 µg	I.M.	None				
6	pXL2	200 µg	I.D.	None				
7	pXL2	200 µg	I.M.	Cardiotoxin				
8	pXL2	200 µg	I.M.	Bupivacaine				

Table 7(a). RSV Serum Neutralizing Titers on Day 49

Group	Antigen	RSV- specific dose	Inoc. route	Nt. antibody titer ( $\log_2/0.05$ ml) in CR no.					Mean titer $\log_2/$ 0.05	Stand. Dev.
				1	2	3	4	5		
1	Placebo	0	I.M.	4	3	2	2	2	2.75	1.0
2	Live RSV	100 CRID50	I.N.	9	9	9	9	9	9	0.0
3	FI-RSV		I.M.	0	4	2	2	2	2.0	1.6
5	pXL2	200 $\mu$ g	I.M.	9	8	8	7	7	8.0	0.8
6	pXL2	200 $\mu$ g	I.D.	5	2	5	5	5	4.3	1.5
7	pXL2	200 $\mu$ g	I.M.	8	8	9	9	9	8.5	0.6
8	pXL2	200 $\mu$ g	I.M.	8	9	6	6	6	7.3	1.5

Table 7(b). RSV Serum Neutralizing Titers on Day 78

Group	Antigen	RSV-specific dose	Inoc. route	Nt. antibody titer ( $\log_2/0.05$ ml) in CR no.					Mean titer $\log_2/0.05$	Stand. Dev.
				1	2	3	4	5		
1	Placebo	0	I.M.	3	2	4	Died		3.0	1.0
2	Live RSV	100 CRID50	I.N.	8	9	8	9		8.5	0.6
3	FI-RSV		I.M.	8	4	6	5		5.8	1.7
5	pXL2	200 $\mu$ g	I.M.	7	8	8	8		7.8	0.5
6	pXL2	200 $\mu$ g	I.D.	8	6	6	Died		6.7	1.2
7	pXL2	200 $\mu$ g	I.M.	8	9	9	8		8.7	0.6
8	pXL2	200 $\mu$ g	I.M.	8	7	9	9		8.3	1.0

Table 8. RSV Titers in Nasal Washes on Day 82

Group	Antigen	RSV-specific dose	Inoc. route	RSV titer ( $\log_{10}/0.05$ ml) in cotton rat no.					Mean titer $\log_{10}/0.05$	Stand. Dev.
				1	2	3	4			
1	Placebo	0	I.M.	3.4	3.3	3.3	Died	3.3	0.1	
2	Live RSV	100 CRID50	I.N.	0	0	0	0	0.0	0.0	
3	FI-RSV		I.M.	0	0	2.8	0	0.7	1.4	
5	pXL2	200 $\mu$ g	I.M.	3.3	2.3	3.3	2.3	2.8	0.6	
6	pXL2	200 $\mu$ g	I.D.	N.D.	N.D.	N.D.	Died	N.D.	N.D.	
7	pXL2	200 $\mu$ g	I.M.	2.3	0	0	3.2	1.4	1.6	
8	pXL2	200 $\mu$ g	I.M.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	

N.D. = non-determined

Table 9. Titers in Lungs on Day 82

Group	Antigen	RSV - specific dose	Inoc. route	RSV titer ( $\log_{10}$ /g lung) in cotton rat no.					Mean titer $\log_{10}$ / 0.05	Stand. Dev.
				1	2	3	4			
1	Placebo	0	I.M.	4.7	4.2	3.7	Died	4.2	0.5	
2	Live RSV	100 CRID50	I.N.	0	0	0	0	0.0	0.0	
3	FI-RSV	$10^3$ PFU	I.M.	0	0	0	0	0.0	0.0	
5	pXL2	200 $\mu$ g	I.M.	0	2.2	0	0	0.6	1.1	
6	pXL2	200 $\mu$ g	I.D.	0	2.2	2.7	3.2	2.0	N.D.	
7	pXL2	200 $\mu$ g	I.M.	0	0	0	0	0.0	0.0	
8	pXL2	200 $\mu$ g	I.M.	0	0	0	0	0.0	N.D.	

N.D. = non-determined

Table 10.

Summary of Histopathology Results Seen in Sections of Cotton Rat Lung.		
Group	Treatment	Major Observations & Comments
1.	Placebo + RSV	Scattered individual and groups of macrophages and polymorphonuclear neutrophils (PMN) in all fields. Overt thickening of septae. Occasional pyknotic cells seen. Overall: mild to moderate inflammation.
2.	Live RSV	Isolated macrophages seen in most fields. Scattered PMN. Overall: minimal inflammation
3.	FI-RSV + RSV	Virtually every field contains numerous mononuclear cells & PMN. Pyknotic cells and debris common. Thickened septae. Evidence of exacerbated disease.
5.	Plasmid + RSV	Isolated macrophages seen in most fields. Occasional PMN seen. Very similar to live virus group.
6.	Plasmid i.d. + RSV	Isolated macrophages seen in most fields. Occasional PMN seen.
7.	Plasmid + CT + RSV	Isolated mononuclear cells and PMN seen in most fields.
8.	Plasmid + Biv + RSV	Scattered mononuclear cells and PMN seen in most fields.
9.	Normal CR Lung	Few leukocytes evidence. Airy, open appearance. Thin septae.

CT = cardiotoxin

Biv = bupivacaine

## REFERENCES

[0074]

- McIntosh K., Canock, R.M. In: Fields BN, Knipe, DM, editors. Virology. New York: Raven Press: 1990: 1045-1072
- Katz SL., In: New Vaccine Development establishing priorities. Vol. 1. Washington: National Academic Press: 1985: 397-409.
- Wertz GW, Sullender WM., Biotechnology 1992; 20: 151-176
- Johnson et al., J. Virol 1987, 61: 3163-3166
- Pemberton et al., J. Gen Virol. 1987, 68: 2177-2182
- Crowe, J.E., Vaccine 1995, 13: 415-421
- WO 90/11092
- WO 94/21797
- Ulmer, Current Opinion, Invest Drugs, 1993, 2: 983-989
- Tang et al., Nature 1992, 356: 152-154
- Furth et al. Analytical Biochemistry, 1992, 205: 365-368
- Pizzorno et al., J. Virol. 1988, 62: 1167-1179
- Chapman, B.S.; Thayer, R.M.; Vincent, K.A. and Haigwood, N.L., Nucl. Acids. Res. 1991, 19: 3979-3986.
- Green, S. Isseman, I., and Sheer, E., Nucl. Acids. Res. 1988, 16: 369
- Breathnack, R. and Harris, B.A., Nucl. Acids Res. 1983, 11: 7119-7136
- Graham, B.S.; Perkins M.D.; Wright, P.F. and Karzon, D.T. J. Mod. Virol. 1988 26: 153-162.
- Nabel, G.J. 1993, Proc. Natl. Acad. Sci. USA 90: 11307-11311.
- Du, R.P et al. 1994., Biotechnology 12: 813-818.
- Prince, G.A. et al, 1978. Ame. J. Pathol. 93: 771-790.
- Karasuyama & Melchers, Eur. J. Immunol. 18, 97-104, 1988
- Wilde David B., et al. 1983 J. Immunol. 131: 2178-2183.
- Ledbetter, J.A., Rouse R., Micklem, H. 1980, J. Exp. Med. 152: 280-295.
- Ozato Keiko, et al, 1982, Transplantation 34: 113-118.
- Davis et al., Vaccine 1994, 12: 1503-1509.

## Claims

1. A plasmid vector, comprising:

5 a first nucleotide sequence encoding a Respiratory Syncytial Virus Fusion (RSV F) protein or a protein capable of inducing antibodies that specifically react with RSV F protein;  
a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV F protein, and  
10 a second nucleotide sequence located adjacent said first nucleotide sequence to enhance the immunoprotective ability of said RSV F protein when expressed *in vivo* from said vector in a host, wherein said second nucleotide sequence comprises a pair of splice sites to prevent aberrant mRNA splicing, whereby substantially all RNA transcribed encodes an RSV F protein.

2. The vector claimed in Claim 1, wherein said first nucleotide sequence encodes a full-length RSV F protein.

3. The vector claimed in Claim 1, wherein said first nucleotide sequence encodes a RSV F protein from which the transmembrane region is absent.

4. The vector claimed in Claim 1, wherein said first nucleotide sequence encodes a full-length RSV F protein and contains a translational stop codon immediately upstream of the start of the transmembrane coding region to prevent translation of the transmembrane coding region.

5. The vector claimed in any one of Claims 1 to 4, wherein said promoter sequence is an immediate early cytomegalovirus promoter.

6. The vector claimed in any one of Claims 1 to 5, wherein said second nucleotide sequence is located between said first nucleotide sequence and said promoter sequence.

7. The vector claimed in any one of Claims 1 to 6, wherein said second nucleotide sequence is that of rabbit  $\beta$ -globin intron II.

8. The vector claimed in any one of Claims 1 to 7 which is pXL2 deposited as ATCC No. 97, 168.

9. The vector claimed in any one of Claims 1 to 7 which is pXL4 deposited as ATCC No. 97, 170.

10. A vector as claimed in any one of Claims 1 to 9 for use as a vaccine.

11. The use of a plasmid vector as claimed in any one of Claims 1 to 9 in the manufacture of a vaccine for immunising a host against disease caused by respiratory syncytial virus (RSV).

12. A method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises:

45 isolating a first nucleotide sequence encoding an RSV F protein or a protein capable of generating antibodies that specifically react with RSV F protein;  
operatively linking said first nucleotide sequence to at least one control sequence to produce a plasmid vector, the control sequence directing expression of said RSV F protein when introduced into a host to produce an immune response to said RSV F protein;  
operatively linking said first nucleotide sequence to a second nucleotide sequence to enhance the immunoprotective ability to said RSV F protein when expressed *in vivo* from the vector in a host, wherein said second nucleotide sequence comprises a pair of splice sites to prevent aberrant mRNA splicing, whereby substantially all RNA transcribed encodes an RSV F protein;  
50 operatively linking said gene to an immunoprotective enhancing sequence to produce an enhanced immunoprotection to said RSV F protein in said host; and  
55 formulating said plasmid vector as a vaccine for *in vivo* administration.

13. A method claimed in Claim 12, wherein said first nucleotide sequence encodes an RSV F protein lacking the transmembrane region.

14. The method claimed in Claim 12 or 13, wherein said at least one control sequence comprises the immediate early cytomegalovirus promoter.

15. The method claimed in any one of Claims 12 to 14, wherein said second nucleotide sequence is introduced into said vector between said control sequence and said gene.

16. The method claimed in any one of Claims 12 to 15, wherein said second nucleotide sequence is that of rabbit  $\beta$ -globin intron II.

17. The method claimed in any one of Claims 12 to 16, wherein said plasmid vector is a plasmid selected from the group consisting of pXL2 (ATCC No. 97, 168) and pXL4 (ATCC No. 97, 170).

18. A method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises:

isolating a first nucleotide sequence encoding an RSV F protein from which the transmembrane region is absent;  
operatively linking said first nucleotide sequence to at least one control sequence to produce a plasmid vector, the control sequence directing expression of said RSV F protein when introduced into a host to produce an immune response to said RSV F protein; and  
formulating said vector as a vaccine for *in vivo* administration.

19. The method claimed in Claim 18, wherein said vector is selected from group consisting of pXL1 (ATCC No. 97, 167) and pXL3 (ATCC No. 97, 169).

20. A diagnostic kit for detecting the presence of a Respiratory Syncytial Virus Fusion (RSV F) protein in a sample, comprising:

(a) a plasmid vector comprising a first nucleotide sequence encoding an RSV F protein, a protein capable of generating antibodies that specifically react with RSV F protein, or a RSV F protein lacking a transmembrane region, and a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV F protein in a host immunised therewith to produce antibodies specific for the RSV F protein;  
(b) isolation means to isolate said RSV F protein-specific antibodies;  
(c) contacting means to contact the isolated RSV F specific antibodies with the sample to produce a complex comprising any RSV F protein present in the sample and RSV F protein specific antibodies, and  
(d) identifying means to determine the production of said complex.

21. The diagnostic kit claimed in Claim 20, wherein said vector is selected from the group consisting of pXL1 (ATCC No. 97, 167), pXL2 (ATCC No. 97, 168), pXL3 (ATCC No. 97, 169) and pXL4 (ATCC No. 97, 170).

## Patentansprüche

1. Ein Plasmidvektor, umfassend:

eine erste Nukleotidsequenz, die ein Respiratory Syncytial Virus Fusion (RSV F)-Protein oder ein Protein kodiert, das fähig ist, Antikörper zu induzieren, die spezifisch mit RSV F-Protein reagieren;  
eine Promotorsequenz, die an die erste Nukleotidsequenz operativ gekoppelt ist, zur Expression des RSV F-Proteins, und  
eine zweite Nukleotidsequenz, die benachbart zur ersten Nukleotidsequenz angeordnet ist, um die Immun-schutz-Fähigkeit des RSV F-Proteins bei Expression *in vivo* aus dem Vektor in einem Wirt zu erhöhen, worin die zweite Nukleotidsequenz ein Paar Spleißstellen umfasst, um aberrantes mRNS-Spleißen zu verhindern, wobei im wesentlichen die gesamte transkribierte RNS ein RSV F-Protein kodiert.

2. Der Vektor gemäß Anspruch 1, worin die erste Nukleotidsequenz ein RSV F-Protein in voller Länge kodiert.

3. Der Vektor gemäß Anspruch 1, worin die erste Nukleotidsequenz ein RSV F-Protein kodiert, bei dem die Trans-membranregion fehlt.

4. Der Vektor gemäß Anspruch 1, worin die erste Nukleotidsequenz ein RSV F-Protein in voller Länge kodiert und ein Translationsstopcodon unmittelbar stromaufwärts vom Start der Transmembran-kodierenden Region enthält, um die Translation der Transmembran-kodierenden Region zu verhindern.

5. Der Vektor gemäß einem der Ansprüche 1 bis 4, worin die Promotorsequenz ein Immediat-Early-Cytomegalovirus-Promotor ist.

6. Der Vektor gemäß einem der Ansprüche 1 bis 5, worin die zweite Nukleotidsequenz zwischen der ersten Nukleotidsequenz und der Promotorsequenz angeordnet ist.

7. Der Vektor gemäß einem der Ansprüche 1 bis 6, worin die zweite Nukleotidsequenz jene von Kaninchen- $\beta$ -Globin-Intron II ist.

8. Der Vektor gemäß einem der Ansprüche 1 bis 7, der pXL2 darstellt, hinterlegt als ATCC Nr. 97, 168.

9. Der Vektor gemäß einem der Ansprüche 1 bis 7, der pXL4 darstellt, hinterlegt als ATCC Nr. 97, 170.

10. Ein Vektor gemäß einem der Ansprüche 1 bis 9 zur Anwendung als Impfstoff.

11. Die Verwendung eines Plasmidvektors gemäß einem der Ansprüche 1 bis 9 bei der Herstellung eines Impfstoffs zur Immunisierung eines Wirts gegen eine Erkrankung, die durch Respiratory Syncytial Virus (RSV) verursacht wird.

12. Ein Verfahren zur Herstellung eines Impfstoffs zum Schutz eines Wirts gegen eine Erkrankung, die durch Infektion mit Respiratory Syncytial Virus (RSV) verursacht wird, umfassend:

Isolieren einer ersten Nukleotidsequenz, die ein RSV F-Protein oder ein Protein kodiert, das fähig ist, Antikörper zu erzeugen, die spezifisch mit dem RSV F-Protein reagieren;  
operatives Verknüpfen der ersten Nukleotidsequenz an wenigstens eine Kontrollsequenz, um einen Plasmidvektor zu ergeben, wobei die Kontrollsequenz die Expression des RSV F-Proteins dirigiert, bei der Einführung in einen Wirt, um eine Immunantwort gegen das RSV F-Protein zu produzieren;  
operatives Verknüpfen der ersten Nukleotidsequenz an eine zweite Nukleotidsequenz, um die Immunschutzfähigkeit gegen das RSV F-Protein zu erhöhen, wenn es *in vivo* aus dem Vektor in einem Wirt exprimiert wird, wobei die zweite Nukleotidsequenz ein Paar Spleißstellen umfasst, um aberrantes mRNS-Spleißen zu verhindern, wobei im wesentlichen die gesamte transkribierte RNS ein RSV F-Protein kodiert;  
operatives Verknüpfen des Gens an eine immunschutzsteigernde Sequenz, um einen gesteigerten Immunschutz gegen das RSV F-Protein in dem Wirt zu produzieren; und  
Formulieren des Plasmidvektors als Impfstoff für eine *in vivo* Verabreichung.

13. Ein Verfahren gemäß Anspruch 12, worin die erste Nukleotidsequenz ein RSV F-Protein kodiert, dem die Transmembranregion fehlt.

14. Das Verfahren gemäß Anspruch 12 oder 13, worin die wenigstens eine Kontrollsequenz den Immediate-Early-Cytomegalovirus-Promotor umfasst.

15. Das Verfahren gemäß einem der Ansprüche 12 bis 14, worin die zweite Nukleotidsequenz in den Vektor zwischen die Kontrollsequenz und das Gen eingeführt wird.

16. Das Verfahren gemäß einem der Ansprüche 12 bis 15, worin die zweite Nukleotidsequenz jene von Kaninchen- $\beta$ -Globin-Intron II ist.

17. Das Verfahren gemäß einem der Ansprüche 12 bis 16, worin der Plasmidvektor ein Plasmid darstellt, das aus der Gruppe bestehend aus pXL2 (ATCC Nr. 97, 168) und pXL4 (ATCC Nr. 97, 170) ausgewählt ist.

18. Ein Verfahren zur Herstellung eines Impfstoffs zum Schutz eines Wirts gegen eine Erkrankung, die durch Infektion mit Respiratory Syncytial Virus (RSV) verursacht ist, umfassend:

Isolieren einer ersten Nukleotidsequenz, die ein RSV F-Protein kodiert, bei dem die Transmembranregion fehlt;

operatives Verknüpfen der ersten Nukleotidsequenz an wenigstens eine Kontrollsequenz, um einen Plasmidvektor zu ergeben, wobei die Kontrollsequenz die Expression des RSV F-Proteins dirigiert, bei Einführung in einen Wirt, um eine Immunantwort gegen das RSV F-Protein zu produzieren; und Formulieren des Vektors als Impfstoff für eine *in vivo* Verabreichung.

19. Das Verfahren gemäß Anspruch 18, worin der Vektor aus der Gruppe ausgewählt ist, die aus pXL1 (ATCC Nr. 97, 167) und pXL3 (ATCC Nr. 97, 169) ausgewählt ist.

20. Ein diagnostisches Kit zum Detektieren des Vorliegens eines Respiratory Syncytial Virus (RSV F)-Proteins in einer Probe, umfassend:

(a) ein Plasmidvektor umfassend eine erste Nukleotidsequenz, die ein RSV F-Protein, ein Protein, das fähig ist, Antikörper zu erzeugen, die spezifisch mit RSV F-Protein reagieren, oder ein RSV F-Protein kodiert, dem eine transmembrane Region fehlt, und eine Promotorsequenz, die operativ an die erste Nukleotidsequenz gekoppelt ist, zur Expression des RSV F-Proteins in einem damit immunisierten Wirt, um Antikörper herzustellen, die spezifisch für das RSV F-Protein sind;

(b) Mittel zum Isolieren, um die RSV F-Protein-spezifischen Antikörper zu isolieren;

(c) Mittel zum Inkontaktbringen, um die isolierten RSV F-spezifischen Antikörper mit der Probe in Kontakt zu bringen, um einen Komplex herzustellen, der jedes RSV F-Protein, das in der Probe vorliegt, und RSV F-Protein-spezifische Antikörper umfasst, und

(d) Mittel zum Identifizieren, um die Herstellung des Komplexes zu bestimmen.

21. Das diagnostische Kit gemäß Anspruch 20, worin der Vektor aus der Gruppe ausgewählt ist, die aus pXL1 (ATCC Nr. 97, 167), pXL2 (ATCC Nr. 97, 168), pXL3 (ATCC Nr. 97, 169) und pXL4 (ATCC Nr. 97, 170) besteht.

## Revendications

1. Vecteur plasmidique, comprenant

une première séquence de nucléotides codant pour une protéine de fusion du virus respiratoire syncytial (F du VRS) ou une protéine capable d'induire la production d'anticorps qui réagissent de façon spécifique avec la protéine F du VRS;

une séquence de promoteur couplée de façon opérationnelle à ladite première séquence de nucléotides pour l'expression de ladite protéine F du VRS, et

une deuxième séquence de nucléotides située en position adjacente à ladite première séquence de nucléotides pour renforcer la capacité immunoprotectrice de ladite protéine F du VRS lorsqu'elle est exprimée *in vivo* dans un hôte à partir dudit vecteur, ladite deuxième séquence de nucléotides comprenant une paire de sites d'épissage pour prévenir un épissage d'ARNm aberrant, grâce à quoi essentiellement tout l'ARN transcrit code pour une protéine F du VRS.

2. Vecteur selon la revendication 1, dans lequel ladite première séquence de nucléotides code pour une protéine F du VRS entière.

3. Vecteur selon la revendication 1, dans lequel ladite première séquence de nucléotides code pour une protéine F du VRS dont la région transmembranaire est absente.

4. Vecteur selon la revendication 1, dans lequel ladite première séquence de nucléotides code pour une protéine F du VRS entière et contient un codon d'arrêt de la traduction immédiatement en amont du début de la région codante transmembranaire pour empêcher la traduction de la région codante transmembranaire.

5. Vecteur selon l'une quelconque des revendications 1 à 4, dans lequel ladite séquence de promoteur est un promoteur précoce immédiat de cytomégalovirus.

6. Vecteur selon l'une quelconque des revendications 1 à 5, dans lequel ladite deuxième séquence de nucléotides est située entre ladite première séquence de nucléotides et ladite séquence de promoteur.

7. Vecteur selon l'une quelconque des revendications 1 à 6, dans lequel ladite deuxième séquence de nucléotides

est celle de l'intron II de la  $\beta$ -globine de lapin.

8. Vecteur selon l'une quelconque des revendications 1 à 7, qui est le pXL2 déposé sous le n° ATCC 97 168.

9. Vecteur selon l'une quelconque des revendications 1 à 7, qui est le pXL4 déposé sous le n° ATCC 97 170.

10. Vecteur selon l'une quelconque des revendications 1 à 9 à utiliser comme vaccin.

11. Utilisation d'un vecteur plasmidique selon l'une quelconque des revendications 1 à 9 dans la préparation d'un vaccin destiné à immuniser un hôte contre une maladie due au virus respiratoire syncytial (VRS).

12. Procédé de production d'un vaccin pour la protection d'un hôte contre une maladie due à une infection par le virus respiratoire syncytial (VRS), qui comprend:

l'isolement d'une première séquence de nucléotides codant pour une protéine F du VRS ou une protéine capable d'induire la production d'anticorps qui réagissent de façon spécifique avec la protéine F du VRS; la liaison opérationnelle de ladite première séquence de nucléotides à au moins une séquence de contrôle pour la production d'un vecteur plasmidique, la séquence de contrôle dirigeant l'expression de ladite protéine F du VRS lorsqu'elle est introduite dans un hôte pour produire une réponse immune à ladite protéine F du VRS; la liaison opérationnelle de ladite première séquence de nucléotides à une deuxième séquence de nucléotides pour renforcer la capacité d'immunoprotection de ladite protéine F du VRS lorsqu'elle est exprimée *in vivo* dans un hôte à partir du vecteur, ladite deuxième séquence de nucléotides comprenant une paire de sites d'épissage pour prévenir un épissage d'ARNm aberrant, grâce à quoi essentiellement tout l'ARN transcrit code pour une protéine F du VRS; la liaison opérationnelle dudit gène à une séquence renforçante immunoprotectrice pour produire une immunoprotection renforcée contre ladite protéine F du VRS dans ledit hôte; et la formulation dudit vecteur plasmidique sous forme d'un vaccin pour une administration *in vivo*.

13. Procédé selon la revendication 12, dans lequel ladite première séquence de nucléotides code pour une protéine F du VRS ne contenant pas la région transmembranaire.

14. Procédé selon la revendication 12 ou 13, dans lequel ladite séquence de contrôle comprend le promoteur précoce immédiat de cytomégalovirus.

15. Procédé selon l'une quelconque des revendications 12 à 14, dans lequel ladite deuxième séquence de nucléotides est introduite dans ledit vecteur entre ladite séquence de contrôle et ledit gène.

16. Procédé selon l'une quelconque des revendications 12 à 15, dans lequel ladite deuxième séquence de nucléotides est celle de l'intron II de  $\beta$ -globine de lapin.

17. Procédé selon l'une quelconque des revendications 12 à 16, dans lequel ledit vecteur plasmidique est un plasmide choisi dans le groupe constitué par le pXL2 (ATCC 97 168) et le pXL4 (ATCC 97 170).

18. Procédé de production d'un vaccin pour la protection d'un hôte contre une maladie due à une infection par le virus respiratoire syncytial (VRS), qui comprend:

l'isolement d'une première séquence de nucléotides codant pour une protéine F du VRS dont la région transmembranaire est absente; la liaison opérationnelle de ladite première séquence de nucléotides à au moins une séquence de contrôle pour la production d'un vecteur plasmidique, la séquence de contrôle dirigeant l'expression de ladite protéine F du VRS lorsqu'elle est introduite dans un hôte pour produire une réponse immune à ladite protéine F du VRS; et la formulation dudit vecteur sous forme d'un vaccin pour une administration *in vivo*.

19. Procédé selon la revendication 18, dans lequel ledit vecteur est choisi dans le groupe constitué par pXL1 (ATCC 97 167) et pXL3 (ATCC 97 169).

20. Trousse de diagnostic pour la détection de la présence d'une protéine de fusion du virus respiratoire syncytial (F

du VRS) dans un échantillon, comprenant:


(a) un vecteur plasmidique comprenant une première séquence de nucléotides codant pour une protéine F du VRS, une protéine capable d'induire la production d'anticorps qui réagissent de façon spécifique avec la protéine F du VRS, ou une protéine F du VRS ne contenant pas de région transmembranaire, et une séquence de promoteur couplée de façon opérationnelle à ladite première séquence de nucléotides pour l'expression de ladite protéine F du VRS dans un hôte immunisé avec cette protéine pour produire des anticorps spécifiques de la protéine F du VRS;

(b) des moyens d'isolement pour isoler lesdits anticorps spécifiques de la protéine F du VRS;

(c) des moyens de mise en contact pour mettre en contact les anticorps spécifiques de la protéine F du VRS isolés avec l'échantillon pour produire un complexe comprenant toute protéine F du VRS présente dans l'échantillon et les anticorps spécifiques de la protéine F du VRS, et

(d) des moyens d'identification pour déterminer la production dudit complexe.

**21.** Trousse de diagnostic selon la revendication 20, dans laquelle ledit vecteur est choisi dans le groupe constitué par le pXL1 (ATCC 97 167), le pXL2 (ATCC 97 168), le pXL3 ( 97 169) et le pXL4 (ATCC 97 170).



**FIG.1**

FIG.2

NUCLEOTIDE SEQUENCE OF THE RSV F GENE.

← SP →

5' MET GLU LEU PRO ILE LEU LYS ALA ASN ALA ILE THR THR ILE LEU ALA VAL THR PHE  
 ATGGAGTTGCCAATCCTCAAAGCAAATGCAATTACCACAATCCTCGTCGAGTCACATTT  
 TACCTCAACGGTTAGGAGTTTCGTTTACGTTAATGGTGTAGGAGCGACGTCAGTGTA  
 10 20 30 40 50 60

CYS PHE ALA SER SER GLN ASN ILE THR GLU GLU PHE TYR GLN SER THR CYS SER ALA VAL  
 TGCTTTTGCTTCTAGTCAAAACATCACTGAAGAATTTTATCAATCAACATGCAGTGCAGTT  
 ACGAAACGAAGATCAGTTTGTAGTGACTTCTTAAATAAGTTAGTTGTACGTCACGTCAA  
 70 80 90 100 110 120

SER LYS GLY TYR LEU SER ALA LEU ARG THR GLY TRP TYR THR SER VAL ILE THR ILE GLU  
 AGCAAAGGCTATCTTAGTGCTCTAAGAAGCTGGTTGGTATACTAGTGTATAACTATAGAA  
 TCGTTTCCGATAGAAATCAGGAGATTCTTGACCAACCATATGATCACAATATTGATATCTT  
 130 140 150 160 170 180

LEU SER ASN ILE LYS GLU ASN LYS CYS ASN GLY THR ASP ALA LYS VAL LYS LEU MET LYS  
 TTAAGTAATATCAAGGAAATAAGTGTAAATGGAACAGATGCTAAGGTAAATGATGAAA  
 AATTCAATTATAGTTCCTTTTATTTCACATTACCTTGCTACGATTCCATTTTAACTACTTT  
 190 200 210 220 230 240

GLN GLU LEU ASP LYS TYR LYS ASN ALA VAL THR GLU LEU GLN LEU MET GLN SER THR  
 CAAGAAATTAGATAAATAAATAATGCTGTAAACAGAAATTGCAGTTGCTCATGCAAGCACA  
 GTTCTTAATCTATTATATTTTTACGACATTGTCTTAAACGTCAACGAGTACGTTTCGTGT  
 250 260 270 280 290 300

PRO ALA ALA ASN ASN ARG ALA ARG ARG GLU LEU PRO ARG PHE MET ASN TYR THR LEU ASN  
 CCAGCAGCAAACAATCGAGCCAGAGAGAACTACCAAGGTTTATGAATTATACACTCAAC  
 GGTGTCGTTTGTAGTCTCGGCTCTTCTTGTGATGGTTCCAAATACTTAATATGTGAGTTG  
 310 320 330 340 350 360

FIG.2 CONT.

F2-F1CLEAVAGE SITE

ASN THR LYS LYS THR ASN VAL THR LEU SER LYS LYS ARG LYS ARG ARG PHE LEU GLY PHE  
 AATACCAAAACCAATGTAACATTAAGCAAGAAAGGAAA8AAGATTCTTGGTTT  
 TTATGGTTTCTTGGTTACATTGTAATTCGTTCTTTTCCCTTTCTTCTAAAGAACCAAAA  
 370 380 390 400 410 420

LEU LEU GLY VAL GLY SER ALA ILE ALA SER GLY ILE ALA VAL SER LYS VAL LEU HIS LEU  
 TTGTTAGGTGTTGGATCTGCAATCGCCAGTGGCATTTGCTGTATCTAAGTCCTGCACTTA  
 AACAAATCCACAACCTAGACGTTAGCGGTACCGTAAACGACATAGATTTCAGGACGTGAAT  
 430 440 450 460 470 480

GLU GLY GLU VAL ASN LYS ILE LYS SER ALA LEU LEU SER THR ASN LYS ALA VAL SER  
 GAAGGAGAGTGAACAAGATCAAAAGTCTCTACTATCCACAACAAGCCGTAGTCAGC  
 CTTCCCTCTTCACTTGTCTTAGTTTTCACGAGATGATAGGTGTTTGTTCGCGCATCAGTCG  
 490 500 510 520 530 540

LEU SER ASN GLY VAL SER VAL LEU THR SER LYS VAL LEU ASP LEU LYS ASN TYR ILE ASP  
 TTATCAAATGGAGTTAGTGTCTTAAACCAGCAAGTGTTAGACCTCAAAAACCTATATAGAT  
 AATAGTTTACCTCAATCACAGAAATTGGTCGTTTCACAATCTGGAGTTTGTGATATATCTA  
 550 560 570 580 590 600

LYS GLN LEU LEU PRO ILE VAL ASN LYS GLN SER CYS ARG ILE SER ASN ILE GLU THR VAL  
 AAACAAATGTTACCTATTTGTGAATAAGCAAAAGCTGCAGAATATCAAAATATAGAAACTGTG  
 TTTGTAAACAATGGATAAACACTTATTCGTTTCGACCGTCTTATAGTTTATATCTTTTGACAC  
 610 620 630 640 650 660

ILE GLU PHE GLN HIS LYS ASN ASN ARG LEU LEU GLU ILE THR ARG GLU PHE SER VAL ASN  
 ATAGAGTTTCCAAACAAGAAACAACAGACTACTAGAGATTACCAGGGAATTTAGTGTAAAT  
 TATCTCAAGGTGTTTCTTGTGTTCTGATGATCTCTAATGGTCCCTTAAATCACAATTAA  
 670 680 690 700 710 720

ALA GLY VAL THR THR PRO VAL SER THR TYR MET LEU THR ASN SER GLU LEU LEU SER LEU  
 GCAGGTGTAACCTACACCTGTAAGCACTTACATGTTAACTAATAGTGAATTTATGTCATTA  
 CGTCCACATTGATGTGGACATTCGTGAATGTACAATTTGATTATCATTAAACAGTAAT  
 730 740 750 760 770 780

## FIG.2 CONT.

```

ILE ASN ASP MET PRO ILE THR ASN ASP GLN LYS LYS LEU MET SER ASN VAL GLN ILE
ATCAATGATATGCCCTATAACAATGATCAGAAAAAGTTAATGTCCAACAATGTTCAAATA
TAGTTACTATACGGATATTGTTTACTAGTCTTTTCAATTACAGGTGTTACAAAGTTTAT
790      800      810      820      830      840

VAL ARG GLN SER TYR SER ILE MET SER ILE ILE LYS GLU VAL LEU ALA TYR VAL
GTTAGACAGCAAAGTTACTCTATCATGTCCATAATAAAAGAGGAAGTCTTTAGCATATGTA
CAATCTGTCGTTTCAATGAGATAGTACAGGTATTATTTTCTCCTTCAGAAATCGTATACAT
850      860      870      880      890      900

VAL GLN LEU PRO LEU TYR GLY VAL ILE ASP THR PRO CYS TRP LYS LEU HIS THR SER PRO
GTACAAATTACCACTATATGGTGTGATAGATACACCTTGTGTGAAATTACACACATCCCCCT
CATGTTAATGGTGATATACCACACTATCTATGTGGAACAACCTTTAATGTGTAGGGGA
910      920      930      940      950      960

LEU CYS THR THR ASN THR LYS GLU GLY SER ASN ILE CYS LEU THR ARG THR ASP ARG GLY
CTATGTACAACCAACAACAAAGAGGTCAACATCTGTTTAAACAAGAAGTACACAGAGGA
GATACATGTTGGTGTGTTTCTTCCAGTTTGTAGACAAATTTGTTCTTGACTGTCCTCCT
970      980      990      1000      1010      1020

TRP TYR CYS ASP ASN ALA GLY SER VAL SER PHE PHE PRO GLN ALA GLU THR CYS LYS VAL
TGGTACTGTGACAAATGCAGGATCAGTATCTTTCTTCCACAAGCTGAACATGTAAGTT
ACCATGACACTGTTACGTCCTAGTCATAGAAAGAGGGGTTCGACTTTGTACATTTTCAA
1030      1040      1050      1060      1070      1080

GLN SER ASN ARG VAL PHE CYS ASP THR MET ASN SER LEU THR LEU PRO SER GLU VAL ASN
CAATCGAATCGAGTATTTTGTGACACAATGAACAGTTTAAACATTACCAGTGAAGTAAAT
GTTAGCTTAGCTCATAAACACTGTGTACTTGTCAAATGTAAATGGTTCACTTCATTTA
1090      1100      1110      1120      1130      1140

LEU CYS ASN VAL ASP ILE PHE ASN PRO LYS TYR ASP CYS LYS ILE MET THR SER LYS THR
CTCTGCAATGTTGACATATTCAATCCCAAATATGATTGTAAAAATTTATGACTTCAAAAACA
GAGACGTTACAACACTGTATAAGTTAGGGTTTATATACTAACATTTTAAATACTGAAGTTTGTG
1150      1160      1170      1180      1190      1200

```

ASP VAL SER SER VAL ILE THR SER LEU GLY ALA ILE VAL SER CYS TYR GLY LYS THR  
 GATGTAAGCAGCTCCGTTATATCACAATCTCTAGGAGCCATTGTGTCATGCTATGCGCAAACT  
 CTACATTCGTCGAGGCAATAGTGTAAGATCCCTCGGTAAACACAGTACGATACCGTTTGTGA  
 1210 1220 1230 1240 1250  
  
 LYS CYS THR ALA SER ASN LYS ASN ARG GLY ILE ILE LYS THR PHE SER ASN GLY CYS ASP  
 AAATGTACAGCATCCCAATAAATAATCGTGGAATCATAAAGACAATTTTCTAAACGGGTGTGAT  
 TTTACATGTCGTAGGTTATTTTATAGCACCTTAGTATTTCTGTAAAGATTGCCCCACACTA  
 1270 1280 1290 1300 1310 1320  
  
 TYR VAL SER ASN LYS GLY VAL ASP THR VAL SER VAL GLY ASN THR LEU TYR TYR VAL ASN  
 TATGTATCAAAATAAAGGGGTGGACACTGTGTCCTGTAGGTAAACACATTTATTTATGTTAAAT  
 ATACATAGTTTATTTCCCCACCTGTGACACACACATCCCATTTGTGTAAATATATACATTTA  
 1330 1340 1350 1360 1370 1380  
  
 LYS GLN GLU GLY LYS SER LEU TYR VAL LYS GLY GLU PRO ILE ILE ASN PHE TYR ASP PRO  
 AAGCAAAGAGGCAAAAGTCTCTATGTATAAAGGTGAACCAATAATAATTTCTATGACCCCA  
 TTCGTTCTTCCCGTTTTCAGAGATACATTTTCCCACTTGGTTATTTTAAAGATACTGGGT  
 1390 1400 1410 1420 1430 1440  
  
 LEU VAL PHE PRO SER ASP GLU PHE ASP ALA SER ILE SER GLN VAL ASN GLU LYS ILE ASN  
 TTAGTATTCCCTCTCTGATGAAATTTGATGCAATCAATATCTCAAGTCAATGAGAAAGATTAAAC  
 AATCATAGGGGAGACTACTTAACCTAACCTACGTAGTTATAGAGTTCAGTTACTCTTCTAATTG  
 1450 1460 1470 1480 1490 1500  
  
 GLN SER LEU ALA PHE ILE ARG LYS SER ASP GLU LEU LEU HIS ASN VAL ASN ALA GLY LYS  
 CAGAGTTTAGCATTATTCTGTAATAATCCGATGAATTATTACATAATGTAAATGCTGGTAA  
 GTCTCAAAATCGTAAATAAGCAATTTAGGCTACTTAATAATGTAATTACATTTACGACCATTT  
 1510 1520 1530 1540 1550 1560  
  
 SER THR THR ASN ILE MET ILE THR THR ILE ILE GLU ILE ILE VAL ILE LEU LEU SER  
 TCAACCAATAATATCATGATGAATACTACTATAATTATAGAGATTATAGTAATAATTGTTATCA  
 AGTTGGTGTATTATAGTACTATTGATGATTAATAATATCTCTAATAATCAATTATAACAATAGT  
 1570 1580 1590 1600 1610 1620

TM

FIG.2 CONT.

LEU ILE ALA VAL GLY LEU LEU LEU TYR CYS LYS ALA ARG SER THR PRO VAL THR LEU SER  
 TTAAATTGCTGTTGGAACCTGCTCCCTATACCTGTAAGGCCAGAAAGCACCCAGTCAACACTAAGC  
 AATTAAACGACAAACCTGACGAGGATATGACATTCCTGGTCTTCGTCAGTGTGATTCG 1630  
 1640 1650 1660 1670 1680  
 LYS, ASP GLN LEU SER GLY ILE ASN ASN ILE ALA PHE SER ASN  
 AAGGATCAACCTGAGTGGTATAAATAATATTGCAATTTAGTAACCTGAATAAAATAGCACCT  
 TTCCTAGTTGACTCACCAATATTATTATAAACGTAATAATCAATGACTTATTTTATCGTGGA 1690  
 1700 1710 1720 1730 1740  
 AATCATGTTCTTACAAATGGTTTACTATCTGCTCATAGACAAACCCATCTATCATTTGGATT  
 TTAGTACAAAGAAATGTTACCAAAATGATAGACGAGTATCTGTTGGGTAGATAGTAACCTAAA 1750  
 1760 1770 1780 1790 1800  
 TCTTAAATACTCTGAACCTTCATCGAAACCTCTTATCTATAAACCATTCTCACTTACACTATT  
 AGAATTTTAGACTTGAAGTAGCTTTTGAGAAATAGATATTGTTGGTAGAGTGAATGTGATAAAT 1810  
 1820 1830 1840 1850 1860  
 AGTAGATTCCCTAGTTTATAGTTATAT 3'  
 TCATCTAAGGATCAAAATATCAATATA 1870  
 1880

NUCLEOTIDE SEQUENCE OF THE RSV F GENE. THE cDNA SEQUENCE IS SHOWN IN THE PLUS (mRNA)  
 STRAND SENSE IN THE 5' TO 3' DIRECTION. THE SIGNAL PEPTIDE (SP) AND THE TRANSMEMBRANE (TM)  
 ANCHOR DOMAIN ARE UNDERLINED. THE PREDICTED F2-F1 CLEAVAGE SITE IS INDICATED BY THE ARROW  
 (↓).

FIG.2 CONT.

FIG.3

## NUCLEOTIDE SEQUENCE OF THE RSV F GENE.

5' ————— SP —————→

MET GLU LEU PRO ILE LEU LYS ALA ASN ALA ILE THR THR ILE LEU ALA VAL THR PHE  
 ATGGAGTTGCCAATCCTCAAGCAATGCAATTACCACAAATCCTCGCTGCAGTCACATTT  
 TACCTCAACCGTTAGGAGTTTCGTTTACGTTAATGGTGTAGGAGCGACGTCAGTGTA  
 10 20 30 40 50 60  
 CYS PHE ALA SER SER GLN ASN ILE THR GLU GLU PHE TYR GLN SER THR CYS SER ALA VAL  
 TGCTTTTGCTTCTAGTCAAAACATCACTGAAGAATTTTATCAATCAACATGCAGTGCAGTT  
 ACGAAACGAAGATCAGTTTGTAGTGACTTCTTAAATAGTTAGTTGTACGTCACGTCAA  
 70 80 90 100 110 120  
 SER LYS GLY TYR LEU SER ALA LEU ARG THR GLY TRP TYR THR SER VAL ILE THR ILE GLU  
 AGCAAGGCTATCTTAGTGCTCTAAGAACTGGTTGGTATACTAGTGTATTAACACTATAGAA  
 TCGTTTCCGATAGAAATCAGGAGATCTTTGACCAACCATATGATCACAATATTGATATCTT  
 130 140 150 160 170 180  
 LEU SER ASN ILE LYS GLU ASN LYS CYS ASN GLY THR ASP ALA LYS VAL LYS LEU MET LYS  
 TTAAGTAATATCAAGGAAATAAGTGTAAATGGAACAGATGCTAAGGTAAATGATGA  
 AATTCAATTATAGTTCCCTTTTATTCACATTTACCTTGTCTACGATTCCATTTTTAACTACTTT  
 190 200 210 220 230 240  
 GLN GLU LEU ASP LYS TYR LYS ASN ALA VAL THR GLU LEU GLN LEU MET GLN SER THR  
 CAAGAAATTAGATAAATAAATAATGCTGTAAACAGAAATTGCAGTTGCTCATGCAAGCACA  
 GTTCTTAATCTATTATATTTTACGACATTTGCTTAAACGTCACGAGTACGTTTCGTGT  
 250 260 270 280 290 300  
 PRO ALA ALA ASN ASN ARG ALA ARG ARG GLU LEU PRO ARG PHE MET ASN TYR THR LEU ASN  
 CCAGCAGCAACAATCGAGCCAGAGAGAACTACCAAGGTTTATGAATTAACACTCAAC  
 GGTCGTCGTTTGTAGCTCGGTCTTCTCTTGATGGTTCCAAATACTTAATATGTGAGTTG  
 310 320 330 340 350 360

## FIG.3 CONT.

F2-F1CLEAVAGE SITE

ASN THR LYS LYS THR ASN VAL THR LEU SER LYS LYS ARG LYS ARG ARG↓PHE LEU GLY PHE  
 AATACCAAAAACCAATGTAACATTAAGCAAGAAAAGGAAA8AAGATTCTTGTTT  
 TTATGGTTTTTTTGGTTACATTGTAAATTCGTTCTTTTCCCTTTCTTCTAAAGAACCAAAA  
 370 380 390 400 410 420

LEU LEU GLY VAL GLY SER ALA ILE ALA SER GLY ILE ALA VAL SER LYS VAL LEU HIS LEU  
 TTGTTAGGTGTTGGATCTGCAATGCCAGTGGCATTGCTGTATCTAAGGTCTGCACCTTA  
 AACATCCACAACCTAGACGTTAGCGGTACCGTAAACGACATAGATTCCAGGACGTGAAT  
 430 440 450 460 470 480

GLU GLY GLU VAL ASN LYS ILE LYS SER ALA LEU LEU SER THR ASN LYS ALA VAL VAL SER  
 GAAGGAGAAGTGAACAAGATCAAAAAGTGTCTTACTATCCACAAACAAGGCCGTAGTCAGC  
 CTTCCCTCTTCACCTTGTTCTAGTTTTCACGAGATGATAGGTGTTGTTCCGGCATCAGTCG  
 490 500 510 520 530 540

LEU SER ASN GLY VAL SER VAL LEU THR SER LYS VAL LEU ASP LEU LYS ASN TYR ILE ASP  
 TTATCAAAATGGAGTTAGTGTCTTAAACCAGCAAGTGTAGACCTCAAAAACCTATATAGAT  
 AATAGTTTACCTCAATCACAGAATTGGTCGTTTCACAATCTGGAGTTTGTGATATATCTA  
 550 560 570 580 590 600

LYS GLN LEU LEU PRO ILE VAL ASN LYS GLN SER CYS ARG ILE SER ASN ILE GLU THR VAL  
 AAACAAATTGTTACCTATTGTGAATAAGCAAGCTGCAGAAATATCAATATAGAAACTGTG  
 TTTGTTAAACAATGGATAACACTTATTTCGTTTCGACGCTTATAGTTTATATCTTTTGACAC  
 610 620 630 640 650 660

ILE GLU PHE GLN HIS LYS ASN ASN ARG LEU LEU GLU ILE THR ARG GLU PHE SER VAL ASN  
 ATAGAGTTCCAACAAGAAACAACAGACTACTAGAGATTACCAGGGAATTTAGTGTAAAT  
 TATCTCAAGGTTGTTTCTTGTGTTGATGATCTCTAATGGTCCCTTAAATCACAATTA  
 670 680 690 700 710 720

ALA GLY VAL THR THR PRO VAL SER THR TYR MET LEU THR ASN SER GLU LEU LEU SER LEU  
 GCAGGTGTAACCTACACCTGTAAGCACTTACATGTAACTAATAGTGAATTTATGTCATTA  
 CGTCCACATTGATGTGGACATTTCGGAATGTACAATTGATTTATCACTTAAATAACAGTAAT  
 730 740 750 760 770 780

## FIG.3 CONT.

```

ILE ASN ASP MET PRO ILE THR ASN ASP GLN LYS LYS LEU MET SER ASN ASN VAL GLN ILE
ATCAATGATATGCCCTATAACAATAATGATCAGAAAAGTTAATGTCCAAACAATGTTCAAATA
TAGTTACTATACCGGATATTGTTTACTAGTCTTTTTCAAATTACAGGTTGTACAAAGTTTAT
790      800      810      820      830      840

VAL ARG GLN SER TYR SER ILE MET SER ILE ILE LYS GLU VAL LEU ALA TYR VAL
GTTAGACAGCAAAGTTACTCTATCATGTCCATAATAAAAGAGGAAGTCTTAGCATATATGTA
CAATCTGTCGTTTCAATGAGATAGTACAGGTATTATTTCCTTCCTTCAGAAATCGTATACAT
850      860      870      880      890      900

VAL GLN LEU PRO LEU TYR GLY VAL ILE ASP THR PRO CYS TRP LYS LEU HIS THR SER PRO
GTACAATTACCACATATATGTTGTGATAGATACACCTTGTGTGGAATTTACACACATCCCCCT
CATGTTAATGGTGATATACCACACTATCTATGTGGAACACCTTTTAATGTGTGTAGGGGA
910      920      930      940      950      960

LEU CYS THR THR ASN THR LYS GLU GLY SER ASN ILE CYS LEU THR ARG THR ASP ARG GLY
CTATGTACAACCAACAACAAGAGGGTCAACATCTGTTTTACAAGAAGTGCACAGAGGA
GATACATGTTGGTTGTGTTTCTTCCAGTTTGTAGACAAATIGTTCTTGACTGTCCT
970      980      990      1000      1010      1020

TRP TYR CYS ASP ASN ALA GLY SER VAL SER PHE PHE PRO GLN ALA GLU THR CYS LYS VAL
TGGTACTGTGACAATGCAGGATCAGTATCTTCTTCCCAAGCTGAAACATGTAAAGTT
ACCATGACACTGTTACGTCCTAGTCATAGAAAGAGGGTGTTCGACTTTGTACATTTTCAA
1030      1040      1050      1060      1070      1080

GLN SER ASN ARG VAL PHE CYS ASP THR MET ASN SER LEU THR LEU PRO SER GLU VAL ASN
CAATCGAATCGAGTATTTTGTGACACAATGAACAGTTTAAACATTACCAAGTGAAGTAAAT
GTTAGCTTAGCTCATATAAACACTGTGTACTTGTCAAATTTGTAATGGTTCACCTTCATTTA
1090      1100      1110      1120      1130      1140

LEU CYS ASN VAL ASP ILE PHE ASN PRO LYS TYR ASP CYS LYS ILE MET THR SER LYS THR
CTCTGCAATGTTGACATATTCAATCCCAATATGATGTGTAATAATTTATGACTTCAAAAACA
GAGACGTTACAACTGTATAAGTTAGGGTTTATATACTAACATTTTAAATACTGAAGTTTGTGT
1150      1160      1170      1180      1190      1200

```

## FIG.3 CONT.

ASP VAL SER SER VAL ILE THR SER LEU GLY ALA ILE VAL SER CYS TYR GLY LYS THR  
 GATGTAAGCAGCTCCGTTATCACAATCTCTAGGAGCCATTGTGTCTATGCTATGGCAAAACT  
 CTACATTCGTCGAGGCAATAGTGTAGAGATCCTCGGTAACACAGTACGATACCGTTTGA  
 1210 1220 1230 1240 1250 1260  
  
 LYS CYS THR ALA SER ASN LYS ASN ARG GLY ILE ILE LYS THR PHE SER ASN GLY CYS ASP  
 AAATGTACAGCATCCAATAAAATCGTGGAATCATAAAGACATTTTCTAACGGGTGTGAT  
 TTACATGTCGTAGGTTATTTTTAGCACCTTAGTATTTCTGTAAAGATTGCCCACACTA  
 1270 1280 1290 1300 1310 1320  
  
 TYR VAL SER ASN LYS GLY VAL ASP THR VAL SER VAL GLY ASN THR LEU TYR TYR VAL ASN  
 TATGTATCAAAATAAAGGGGTGGACACTGTGTCTGTAGGTAACACATTTATATATGTAAT  
 ATACATAGTTTATTTCCCCACCTGTGACACAGACATCCATTGTGTAATAATAACATTTA  
 1330 1340 1350 1360 1370 1380  
  
 LYS GLN GLU GLY LYS SER LEU TYR VAL LYS GLY GLU PRO ILE ILE ASN PHE TYR ASP PRO  
 AAGCAAGAAGGCAAAAGTCTCTATGTAAAGGTGAACCAATAAJAAATTTCTATGACCCA  
 TTCGTTCTTCCGTTTTCAGAGATACATTTTCCACTTGGTTATTTAAAGATACTGGGT  
 1390 1400 1410 1420 1430 1440  
  
 LEU VAL PHE PRO SER ASP GLU PHE ASP ALA SER ILE SER GLN VAL ASN GLU LYS ILE ASN  
 TTAGTATTTCCCTCTGATGAATTTGATGCATCAATATCTCAAGTCAATGAGAAGATTAAAC  
 AATCATAAGGGGAGACTACTTTAAACTACGTAGTTATAGAGTTTCAGTTACTTCTCTAATTG  
 1450 1460 1470 1480 1490 1500  
  
 GLN SER LEU ALA PHE ILE ARG LYS SER ASP GLU LEU LEU HIS ASN VAL ASN ALA GLY LYS  
 CAGAGTTTAGCATTTATTCGTAATCCGATGAATTAATACATAATGTAATGCTGTAAAA  
 GTCTCAAATCGTAAATAAGCATTTAGGCTACTTAATAATGTATTACATTTACGACCATT  
 1510 1520 1530 1540 1550 1560  
  
 SER THR THR ASN ILE MET Thr Stop Stop Bam HI  
 TCAACCACAAATATCATGACTTGATAATGAGGATCC  
 AGTTGGTGTTTATAGTACTGAACATATTACTCCTAGG  
 1570




FIG.4A




FIG.4B




FIG.4C




FIG.4D




FIG.5A




FIG.5B




FIG.5C




FIG.5D




FIG.6A




FIG.6B




FIG.6C




FIG.6D




FIG.7A




FIG.7B




FIG.7C




FIG.7D

FIG.8

```

401 TTGGGGACCC TTGATTGTTT TTTCTTTTTC GCTATTGTAA AATTCATGTT
451 ATATGGAGGG GGCAAAGTTT TCAGGGTGTT GTTTAGAATG GGAAGATGTC
501 CCTTGTATCA CCATGGACCC TCATGATAAT TTTTGTTCCTT TCACTTCTA
551 CTCTGTTGAC AACCATTGTC TCCTCTTATT TTCTTTTTCAT TTTCTGTAAAC
601 TTTTTCGTTA AACTTTAGCT TGCATTTGTA ACGAATTTT AAATTCACCTT
651 TTGTTTATTT GTCAGATTGT AAGTACTTTC TCTAATCACCT TTTTTTTCAA
701 GGCAATCAGG GTATATTATA TTGTACTTCA GCACAGTTT AGAGAACAAT
751 TGTTATAAAT AAATGATAAG GTAGAATAAT TCTGCATATA AATTCGGCT
801 GGCGTGGAAA TATTCTTATT GGTAAGAAACA ACTACATCCTT GGTCATCATC
851 CTGCCCTTCT CTTTATGGTT ACAATGATAT ACACTGTTTG AGATGAGGAT
901 AAAATACTCT GAGTCCAAAC CGGGCCCCCTC TGCTAACCAT GTTCATGCCCT
951 TCTTCTTTT CCTACAG
GTGAGT

```